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Abstract
The pre-treatment of patients with clopidogrel before primary percutaneous coronary intervention (PCI)
has been shown to lower the risk of complications that could lead to heart attack or stroke during the
procedure. However, the proper administration of clopidogrel requires the measurement of the patient’s
drug resistance due to its inherent variation across the population. Approximately 1.1 million PCIs were
performed in the US alone in 2008. As the patient population is becoming increasingly aware of the
benefits of clopidogrel treatment prior to PCI, there is an ever-expanding market potential for clopidogrel
resistance screening devices. As most of the existing devices utilize traditional test-tube-scale bench-top
technology that usually sets limitations on the throughput and applicability of the test itself, the market
demands a device that not only minimizes the cost per test but also produces consistent and
comprehensive results. In this report, guided by the innovation map, we are able to link soft lithography in
combination with micro-patterning technology to the customer’s requirements, and come up with a
higher-throughput system that meets the market demand. Our system consists of two parts: the chip and
the device. We focus our design effort primarily on the chip, in which micro-channel layout, dry reagent
dissolution, reagent mixing and reservoir volume design are carefully worked out. On the other hand, the
design of the device is discussed briefly, but production is assumed to be outsourced. With the cost
estimates from suppliers and the assumed expected market share to be 50%, the net present value is
computed to be about 45 million, indicating a lucrative return to investors.
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Part 1 Introduction
1.1

Abstract
The pre-treatment of patients with clopidogrel before primary percutaneous coronary

intervention (PCI) has been shown to lower the risk of complications that could lead to heart
attack or stroke during the procedure.

However, the proper administration of clopidogrel

requires the measurement of the patient’s drug resistance due to its inherent variation across the
population. Approximately 1.1 million PCIs were performed in the US alone in 2008. As the
patient population is becoming increasingly aware of the benefits of clopidogrel treatment prior
to PCI, there is an ever-expanding market potential for clopidogrel resistance screening devices.
As most of the existing devices utilize traditional test-tube-scale bench-top technology that
usually sets limitations on the throughput and applicability of the test itself, the market demands
a device that not only minimizes the cost per test but also produces consistent and
comprehensive results. In this report, guided by the innovation map, we are able to link soft
lithography in combination with micro-patterning technology to the customer’s requirements,
and come up with a higher-throughput system that meets the market demand.

Our system

consists of two parts: the chip and the device. We focus our design effort primarily on the chip,
in which micro-channel layout, dry reagent dissolution, reagent mixing and reservoir volume
design are carefully worked out. On the other hand, the design of the device is discussed briefly,
but production is assumed to be outsourced. With the cost estimates from suppliers and the
assumed expected market share to be 50%, the net present value is computed to be about 45
million, indicating a lucrative return to investors.

-1-

1.2

1.2.1

Introduction
Motivation
In 2008, 1.1 million Americans with circulatory complications underwent Percutaneous

Coronary Intervention (PCI) procedures. Often, the success rate of PCI is limited by the risk of
adverse clotting events. Research supported by angiographic evaluation evidence has shown that
clopidogrel (Plavix) 1 can reduce these events during the procedure and chances of developing
further complication if administered prior to the procedure. However, some patients exhibit poor
response to the drug and require a higher dose to achieve a therapeutic level of the active drug
metabolite in circulation. The current evaluation of Plavix resistance requires laboratory scale
manual mixing of the drug with the patient’s blood and the subsequent observation of platelet
function. Progress has been made to increase the throughput and the cost-effectiveness of this
test, yet none of the existing technologies satisfies the customer’s desires of small blood volume,
high throughput and automated operation.
Since its discovery and development by Bristol-Myers Squibb, clopidogrel has been
marketed as Plavix worldwide to 110 different countries with annual sales of $5.9 billion and
exhibiting growth rate of 20%. (1) The market potential for Plavix resistance screening devices is
becoming apparent. The goal of this design project is to come up with an automated machine
that uses disposable microfluidic chips to quantify the patient’s resistance to Plavix based on a
blood volume of less than 1 milliliter.

1

“clopidogrel” is the generic name for Plavix and both terms will be used interchangeably
throughout this report.
-2-

1.2.2

Project Charter and Scope
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1.2.3

Technology-Readiness Assessment
An innovation map (See Figure 1-1) is used to address the need for new technologies

when preparing a new product. As discussed by Seider et al., an innovation map has six levels.
Listing these levels from top to bottom, they are: customer-value proposition, products, product
technology, technical differentiation, process/manufacturing technology, and materials
technology. The map connects these levels by stating which new technological features will be
used in the development of the product. (2)
The innovation map shows the manufacturing of the Multi-Channel Coagulation
Resistance Assay (MCCRA) System which consists of a microfluidic chip and a device to run
the physical test and display the results to the practitioner. The technologies used to fabricate
these items include soft lithography and replicate molding for the chip and outsourcing for the
device. The technical differentials are the features that set the MCCRA System apart from other
competing products. The ability to test for varying resistances in patients on a single chip is a
new concept that makes this new product very valuable.

The device feature for a quick

turnaround test time is important for hospitals as well as patients. All of these specifics will be
discussed in more detail later on. The market and innovative features of the system make these
new technologies justifiable.

-4-
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Figure 1-1 Innovation Map
The innovation map shows the new technologies that will be used in a product.
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1.2.4

Report Contents Summary

Our design report can be broken down into four major parts. Part 1 addresses the motivation
behind this project, presents a project charter, and briefs on the innovation map that guides us
through the development of our product. Part 2 reviews the physiology of blood clots, the
molecular pathways of clopidogrel, chip manufacture, and market potential analysis. Part 3 deals
in depth with chip design, including chip design and manufacture, financial analysis, and a
summary of the box components in succinct terms since the focus of this project is on the chip.
Part 4 describes the post-design considerations, which include FDA approval and areas of future
research and development.
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Part 2 Concept Stage
2.1

2.1.1

Physiology of Blood Clotting
The Basics of Blood
The blood flowing through the human body, known as whole blood, has four main

components: plasma, red blood cells (erythrocytes), white blood cells (leukocytes), and platelets
(thrombocytes). The plasma comprises about 55% of the whole blood, while the other 45%
consists of the three blood cells.
Plasma is about 90% water, with the other 10% consisting of substances such as proteins,
electrolytes, hormones, vitamins and cholesterol. This liquid is responsible for transport of blood
components through the body.
Red blood cells are the second most prevalent component of whole blood, accounting for
about 40-45% of its make-up. These cells are primarily responsible for the transport of carbon
dioxide and oxygen to and from the lungs, respectively, through the protein hemoglobin found
inside the cells.
White bloods cells compose only about 1% of the total volume of whole blood, and are
responsible for protecting the body against infection.
Platelets are anuclear blood cells that gather at the location of an injury to allow
coagulation to occur at the site. Deviations in the platelet count from normal values (300,000 to
600,000 per μL) can be very dangerous to the body. Too many platelets can lead to unwanted
clotting, which can in turn cause heart attack or stroke. Too few platelets, however, can lead to
the inability to clot normally and thus cause excessive bleeding. (3)

-7-

2.1.2

Hemostasis
Hemostasis refers to the complex network of steps leading to the formation of a clot at

the site of a damaged blood vessel. Its purpose is to stop and prevent further loss of blood at the
damaged location.

(4)

The process involves three major components which are platelets,

endothelial cells, and blood clotting proteins. Under normal conditions (i.e. no damage to the
blood vessel), endothelial cells line the interior of the blood vessel and prevent clots from
forming on the walls by acting as a physical barrier to the formation as well as by releasing nitric
oxide, prostacyclin and other molecules that inhibit platelet aggregation, while platelets and
blood-clotting proteins are found in the blood plasma in an “inactive form” until activated by
injury. (5) (6) Hemostasis can be broken down into three categories, known as primary hemostasis,
secondary hemostasis and tertiary hemostasis. It is important to note that all three categories in
fact occur simultaneously.

They are

only divided in this way for easier
understanding of mechanisms, not to
delineate three sequential steps in the
process. (7)
Primary hemostasis refers to the
formation of the platelet plug. When
injury occurs, the layer of endothelial
cells within the vessel is broken and
subendothelial surfaces are exposed.
Without the inhibition of the endothelial

Figure 2-1 Coagulation Cascade
The solid black lines represent activating factors and the complexes
that they activate.

cells, platelets begin to adhere to the wall
-8-

of the vessel at the damaged location. The rate of platelet adhesion at this site is increased by the
local vasoconstriction that is triggered upon breakage of the blood vessel. (6) Vasoconstriction
slows down blood flow and reduces the rate of blood lost by narrowing the blood vessel in the
injured area.

Simultaneously, another area of the vessel is subjected to vasodilation, or

expansion, so as to balance the narrowing effect. (8)
In the high shear rate conditions that exist at the site of an injury, von Willebrand factor
(vWf) is responsible for platelet adhesion to the subendothelium by binding with glycoprotein
Ib-IX which is found in the membrane of the platelets. (In areas such as the veins where low
sheer rate conditions exist, the same process is controlled by collagen exposed during injury, not
vWf. Instead, the fibrinogen binds to a platelet receptor known as glycoprotein Ia/IIa, or integrin
α 2 β 1 ). Upon adhesion to the wall of the blood vessel, the platelets are activated, causing them to
morph. The change in shape triggers the activation of glycoprotein IIb/IIIa (or integrin α IIb β 3 a
fibrinogen receptor located on the platelet’s surface). In addition to shape change, the activated
platelets release dense granules (which contain serotonin and ADP), thromboxane A 2 (TXA 2 )
and plated activating factor (PAF). The latter two secretions are vasoconstriction triggers as well
as agonists for platelet aggregation. The platelet agonists TXA 2 , PAF, ADP, and serotonin
activate additional platelets, causing them to attach to those that have already adhered to the
vessel wall. Thrombin, which is created via the coagulation cascade (which will be explained
later), also acts as a platelet agonist. Fibrinogen serves as the primary mediator of platelet
aggregation by binding to α IIb β 3 on two adjacent platelets, thus forming the primary platelet plug.
(6)

-9-

Secondary hemostasis refers to the production of fibrin via the coagulation cascade (See
Figure 2-1). (9) The cascade is commonly broken down into the extrinsic pathway, the intrinsic
pathway, and the common pathway. (10)
The extrinsic pathway is responsible for the initiation of the coagulation cascade in vivo.
First, tissue factor is released from monocytes, endothelial cells, and subendothelial cells (the
amount released is amplified by cytokines). Then, tissue factor binds to factor VII, which in turn
activates factor X to Xa. Factor Xa, small levels of constitutively active factor Va, platelet
phospholipids, and calcium activate the conversion of prothrombin to thrombin. Although tissue
factor pathway inhibitor quickly inhibits this conversion, only the small amount of thrombin that
is created is needed in order to activate the common pathway. (10) The intrinsic pathway is not
believed to have a function in vivo¸ but is responsible for initiation from negatively charged
synthetic surfaces, such as glass or plastic.
While the purpose of the extrinsic pathway is to initiate the coagulation cascade, the
common pathway is responsible for amplifying the cascade. This amplification is triggered by
the thrombin that is produced by the extrinsic pathway. The thrombin activates factor IX and
factor VIII to XIa and VIIIa. Then, VIIa and IXa, phospholipids, and calcium all act to amplify
the activation of factor X. By amplifying factor Xa and Va production, large amounts of the
prothrombinase complex (XaVa) are formed and large amounts of thrombin are generated. The
thrombin then cleaves fibrinogen into soluble fibrin monomers, which polymerize into fibrin
protofibrils which then will polymerize into fibrin fibers which add mechanical stability to the
forming platelet plug. Factor XIII, which is also activated by thrombin, then works with calcium
to stabilize the fibrin polymer by cross-linking the fibrin fibers. The stabilized polymer is
insoluble cross-linked fibrin. (10)
- 10 -

Tertiary hemostasis refers to the formation of the enzyme plasmin, which is responsible
for breaking down the blood clot (known as fibrinolysis). When the coagulation cascade is
activated, endothelial cells release tissue plasminogen activator, or tPA. The tPA converts the
plasminogen found in the clot into plasmin. The plasmin then creates fibrin and fibrinogen
degradation products by proteolytically cleaving the fibrin and fibrinogen that are in the clot.
However, in order for tPA to activate the plasminogen, fibrin must be present. This restricts
activation to only where thrombus is formed, keeping the tPA from undesirably destroying
fibrinogen, factor V or factor VIII.

In addition to tPA, plasminogen can be activated by

urokinase, kallikrein or factor XIIa. (11)

Clopidogrel (Plavix)

2.2

2.2.1

Mechanism of Action
Adenosine diphosphate (ADP)

binds to platelet G-protein linked surface
receptors P2Y 1 and P2Y 12 (Figure 2-2).
Upon binding, the G q linked P2Y 1
receptor activates phospholipase C and
causes the cytosolic surge of Ca++, which
is

responsible

for

the

immediate

conformational change. The activated G i

Figure 2-2: ADP mediated activation of platelet aggregation (14)

linked receptor P2Y 12 detaches its α subunit from the β subunit, which lead to two independent
signaling pathways. The α subunit inhibits adenylyl cyclase (AC), which catalyzes the formation
of cyclic adenosine monophosphate (cAMP). The reduced level of cAMP causes a decreased
- 11 -

level of the specific protein kinases that phosphorylate the vasodilator-stimulated phosphoprotein
(VASP). The phosphorylated form of VASP inhibits GP IIb/IIIa receptor, which is responsible
for platelet aggregation. In contrast, the β subunit activates the phosphatidylinositol 3-kinase
(PI3K) which is an important intermediate signaling molecule for dense and α-granule secretion.
All told, P 2 Y 12 signaling both induces inside-out signaling, activating the α IIb β 3 integrins, and
induces granule release.
Clopidogrel requires oxidation by the hepatic cytochrome P450 to result in the opening
of the thiophene ring and the forming of a carboxyl and thiol group. However, only a small
proportion of the clopidogrel undergoes oxidation by CYP450 in vivo.

(12)

The thiol group

irreversibly binds to the platelet G i -protein linked ADP surface receptor, P2Y 12 , through a
covalent disulfide bridge, thus reducing the number of inducible P2Y 12 receptors on the platelet
surface that indirectly disable α IIb β 3 activation. Without the activated α IIb β 3 integrins, fibrin and
fibrinogen cannot bind platelets together.
2.2.2

Variability of Clopidogel Resistance
Five to ten percent of the patients treated with clopidogrel exhibit resistance. Of that five

to ten percent, 25% of these patients are reported to be partially responsive in standard platelet
assays. (13) The causes of clopidogrel resistance cannot yet be elucidated and are still areas of
active research. Yet many studies seem to agree that there are certain areas of research that seem
most relevant to clopidogrel resistance: 1) genetic variation of the P2Y 12 and P-450 CYP3A; 2)
extent of P2Y 1 -dependent platelet aggregation; 3) accelerated platelet turnover; 4) interaction
with medication that involves cytochrome P-450 CYP3A4.

- 12 -

2.2.2.1 Polymorphisms of P2Y 12 and P-450 CYP3A
There are 2 haplotypes, designated H1 and H2, associated with P2Y 12 that have been
identified. The H2 haplotype is associated with increased maximal platelet aggregation in
response to ADP. (14) Variations of the promoter region of P2Y 12 have been observed to increase
transcriptional efficiency in the H2 haplotype; this partially explains why H2 carriers exhibit
higher number of P2Y 12 receptors on the platelet surface than non-carriers.
Likewise, the variation of CYP3A expression in different individuals has been identified.
The genetic basis for this difference has not yet been identified, but it is possible to use the
erythromycin breath test to determine an individual’s CYP3A activity. (15) Lau et al. has shown
that the positive correlation between CYP3A activity and clopidogrel’s effectiveness.
2.2.2.2 Extent of P2Y 1 -Dependent Platelet Aggregation
Studies have found that activation via the P2Y 1 receptor alone can induce transient
platelet aggregation. (14) The expression level of P2Y 1 receptor on the platelet surface is different
across the patient population.
2.2.2.3 Different Platelet Turnover Rates
In times of stress, the bone marrow has accelerated platelet production. The replenished
platelets carry P2Y 12 receptors that are unexposed to clopidogrel.

(13)

This dramatically

decreases the duration of clopidogrel’s anti-clotting effectiveness.
2.2.2.4 Interaction with Other Medications Involving P450
Drugs that involve cytochrome P450 have been postulated to reduce the effectiveness of
clopidogrel.

For example, studies have shown that atorvastatin (Lipitor), used to treat

hypercholesteremia, also requires P-450 CYP3A4 metabolism to become active. (16) Patients with
- 13 -

atherosclerotic disease are often treated for hypercholesteremia with both atorvastatin and
clopidogrel. The former is shown to competitively inhibit the latter’s anti-platelet activities.
2.2.3

Time Dependent Plavix Resistance
The percentage of platelet aggregation at a certain time post clopidogrel treatment varies

across patient population and resistance to the drug diminishes given more time. For example,
Gurbel et al. correlates the frequency of patients and absolute change in platelet aggregation after
the drug treatment at 2 hr, 24 hr, 5 days and 30 days; the percentage of patients who are resistant
to clopidogrel is found to be 63%, 31%, 31% and 15% respectively, where resistance is defined
empirically by the study. (17) One possible explanation is that each patient’s hepatic cytochrome
P450 CYP3A rate of metabolism is different.
2.3

Chip Manufacture with PDMS
The microfluidic chip that will be at the heart of the POC device will be constructed of an

elastomer known as polydimethylsiloxane. Abbreviated as PDMS, it possesses an array of
qualities that make it an ideal choice for use in fabrication. First, features with sub 0.1 micron
fidelity can be formed, meaning that many channels of small width are able to be fabricated on a
single chip. Second, it is thermally and electrically insulating. Third, polydimethylsiloxane is
mostly non-reactive towards reactants used. Also, PDMS possesses good bio-compatibility and
can easily be surface-modified to make it biologically inert, which is an especially important
characteristic in our system. In addition, the Young’s Modulus is tunable, allowing one to adjust
the elastomeric properties of PDMS to that required for the system. Finally, and most important,
a layer of PDMS is optically transparent for a wide range of light wavelengths, down to 240
nanometers. The usefulness of this last characteristic of PDMS is useful because a detection
system involving visible light will be used for monitoring the blood clotting.
- 14 -

Polydimethlysiloxane will be purchased from any number of chemical suppliers, and,
once large-scale manufacturing commences, will be purchased in massive bulk installments.
PDMS is supplied in a two parts: a base and curing agent. When the two are mixed, the silicon
hydride groups present in the curing agent react with vinyl groups present in the base,
polymerizing and forming an elastomeric solid.

The base to curing agent proportions are

adjustable values, which lead to different degrees of elastomeric solids and thus forms the basis
for the tunable Young’s Modulus of PDMS.
The manufacture of PDMS begins by the creation of a mask, or master. This mask has a
reverse image of the intended pattern and is usually created via photolithography. Once the
PDMS is mixed using the desired amounts of base and curing agents, it is poured onto the mask
and allowed to harden. The device is peeled off the mask and attached to another substrate for
further patterning.
An important manufacturing advantage of PDMS is its ability to be sealed to other
homogenous or heterogeneous layers of PDMS, which might be necessary in the construction of
a multilayer device. In addition this sealing can be done either reversibly or irreversibly, making
the possibility of peeling the layers apart to inspect the device after use possible.
By using PDMS, the ability to mold a number of components becomes possible. Upon
fabrication, valves, pumps, mixers, switches and a number of other miniaturized components can
be fabricated. Moving up a level of complexity, the potential exists for the combination of these
in sequence to form microfluidic unit operations. (18)
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2.4

Lap-On-a-Chip Microfluidic Platform
Lab-on-a-chip technology involving microfluidics is continuously growing in popularity,

especially in the biotechnological, medical, and pharmaceutical industries.

By definition,

microfluidics deals with the behavior, flow, and precise control of fluids that move through
channels and areas that are of a micro-, nano-, or pico- scale. Features of a microfluidic setup
include small volumes and sizes as well as low energy consumption.
Microfluidic platforms have many appealing features, such as a simple and well defined set
of fluidic unit operations and a low cost for fabrication.

Some examples of fluidic unit

operations are fluid transport, fluid mixing, and separation or concentration of molecules.
“Ideally, the set of unit operations will be connected in a monolithically integrated way so the
platform allows for a seamless and simple integration of different fluids, which will give the
platform a significant advantage over more complicated models” (19).
2.5

Customer Requirements
Considering the needs and features required by potential customers is crucial to designing

a new product and will most likely determine whether the product succeeds or fails. Customer
requirements are determined by analyzing data from the market survey and researching
competing products. Once a list of customer requirements is compiled, each requirement is
given a weighting factor to designate its degree of importance and is also classified as either
fitness-to-standard (FTS) or new-unique-difficult (NUD).
customer requirements.
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(2)

Table 2-1 shows the desired

Customer
Requirement

Product Requirements

Type

Weighting
Factor (%)

NUD

40

FTS

35

Multiple tests simultaneously
High Throughput

Small Sample
Fast turnaround time
Instrument/measurement quality

Accuracy

Reagent quality
Sample quality

Sensitivity

Detection limit

FTS

15

Low Cost

Small reaction amounts

NUD

10

Table 2-1 Customer Requirements
The table above lists the customer requirements compiled from market research. Each requirement
corresponds to product requirements, a type, and a weighting factor.

2.6

2.6.1

Critical-to-Quality Variables—Product Requirements
Critical-to-Quality (CTQ) Variables
The customer requirements from the previous section must be translated into technical

requirements that can be manufactured and used in the design of the device. These technical
requirements are also called critical-to-quality variables (CTQ) and relate to specific target
values. The target values have been determined by researching competing products such as
Accumetrics VerifyNow P2Y 12 Assay, Siemens PFA-100 System, and Helena AggRAM Module
and by reviewing market survey data. The technical requirements and target values are shown
below in Table 2-2.
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Customer/Product Requirement

Technical Requirement (CTQ)

Target (per chip)

Multiple Tests Simultaneously

Multiple Concentrations of MRS 2395

4 concentrations of MRS 2395

Small Sample

Whole Blood Samples

360 μL

Fast Turnaround Time

Total Assay Time

~ 5 minutes + 10 minute incubation

Instrument/Measurement Quality

Advanced Error Verification System

Multiple Tests/[MRS]
2 channels/MRS concentration

Reagent Quality

Chemical Purity

> 95% pure

Sample Quality

Directly From Patient

Anti-coagulated blood

Detection Limit

Visible Light Detection

380-750 nm

ADP Volume

160 nL

MRS 2395 Mass

0.06327 mg

Collagen Volume

32 nL

Small Reaction Amounts

Table 2-2 Critical-to-Quality Variables
The product requirements are translated into technical requirements and given a target to reach.

2.6.2

House of Quality
The House of Quality (HOQ) relates the customer requirements to the overall product

requirements and consists of six sections. The first section is a list of the customer requirements
and the second section lists the technical requirements associated with the customer requirements.
The third section consists of a matrix that shows the relationships between the customer and
technical requirements, showing whether or not the technical requirement exists for a certain
customer requirement. The fourth section, or the top of the house, shows the synergies and
conflicts among the technical requirements. In this section, a plus sign is used to designate that
both variables are increasing or decreasing while a minus sign is used to show if one variable
increases while the other one decreases or vice versa. If no relationship exists between the
variables, the space is left blank.

For the House of Quality in Figure 2-3, the technical

requirements do not directly relate to each other so the top of the house is blank. The final
section displays the weighting factors for the customer requirements which were already
determined in the customer requirements table. (2)
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Figure 2-3 House of Quality
The House of Quality relates the customer requirements to the overall product requirements. The customer requirements and weighting factors are highlighted in
green and the technical requirements are highlighted in light orange.

Small Reaction Volume

Low Cost (NUD)

Detection Limit

Sensitivity (FTS)

Sample Quality

Reagent Quality

Instrument/Measurement Quality

Accuracy (FTS)

Fast Turnaround Time

Small Sample

Multiple Tests Simultaneously

High Throughput (NUD)

Customer Requirement

1

1

1

1

1

1

1

1

1

2.7

Product Concepts
“The Pugh Matrix is used to compare how well the NUD requirements are satisfied by

the device concept versus its leading competitor”

(2)

.

Based on data accumulated from

researching the market, it was determined that Helena’s AggRAM Module and Analyzer is the
main rival of the MCCRA System. The requirements are listed and the current solutions to those
requirements used by the AggRAM Module are presented in Table 2-3. Our system’s alternative
for each requirement is ranked as inferior, superior, or equal to our competitor’s solution. As
shown in Table 2-3, the MCCRA System has many superior concepts when compared to the
competition such as a better error detection system, faster turnaround time, lower cost, and
smaller sample.

Requirement

Reference Concept
(Helena's AggRAM Module and Analyzer)

MCCRA
System

Multiple Tests
Simultaneously

Up to 4 tests simultaneously

0

Small Sample

900 µL

+

Fast Turnaround Time

5 minutes plus 45 minute preparation/incubation time

+

Advanced Error Detection
System

Baseline channel for 100% aggregation

+

Low Cost

$7,995 for device and $14,995 for analyzer
$70 for reagents and cuvettes

Table 2-3 Pugh Matrix
The Pugh Matrix compares our product against its competitor in regards to fulfilling requirements.
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+

2.8

2.8.1

Market and Competitive Analysis
Accumetrics—VerifyNow P2Y 12 Assay
The Accumetrics VerifyNow System uses an optical detection system and a single

channel assay to measure platelet aggregation. The P2Y 12 Assay, one form of a test that can be
performed by the system, is designed to measure how well clopidogrel blocks the P2Y 12
receptors on the platelets by using light transmittance. This test is performed using the whole
blood of a patient who is already being medicated with clopidogrel.
The P2Y 12 Assay uses 2 mL of whole blood and has a 3 minute runtime, not including an
incubation period of about 10 minutes. During the test, the adenosine diphosphate (ADP) is used
as an agonist to induce the activation of platelets which are present in whole blood. The
activated platelets attach to the fibrinogen coated beads and aggregation occurs. While this
reaction is occurring in one channel, a baseline channel containing thrombin and fibrinogen
coated beads is being run simultaneously. Thrombin receptors are strong platelet activators that
work independently from the P2Y 12 receptor so
this baseline channel is used as the control.
Light transmittance is the method of
detection used for this system. The change in
optical signal in the assay channel is measured
and reported in P2Y 12 Reaction Units (PRU).
The change in transmittance is also measured in
the baseline channel. The percent inhibition is
calculated by the percentage difference between
the PRU and baseline channel results.
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Figure 2-4 Accumetrics VerifyNow System (20)

The list price for the VerifyNow System is $8,000 and the Assay Kit costs $1,250 for 25
tests. The system is also beneficial because it can be used with assay kits involving aspirin as
well as α IIb β 3 inhibitors. (20)

2.8.2

Siemens—PFA-100 System
The Siemens PFA-100 System detects platelet dysfunction and is the first commercially

available in vitro test to incorporate the high-shear flow as well as platelet adhesion and
aggregation that would occur after a vascular injury. This test is designed to decipher the
amount of time in which the platelets will coagulate and close a hole which represents a vascular
injury. It is assumed the patient is already taking clopidogrel in order for this test to give usable
results.
This test uses 800 µL of citrated whole blood and has a runtime of 5 minutes, not
including a 15 minute incubation period. The
system uses a membrane of collagen and ADP
to monitor platelet interaction.

The whole

blood flows through a 150 µm port through
the collagen/ADP membrane at a shear rate of
4,000-5,000/s.

The time required for the

platelets to close the aperture shows the
platelet hemostatic capacity. (21)

Figure 2-5 Siemens PFA-100 System (21)

The list price for the PFA-100 System is $15,000 and the ADP/Collagen Test Cartridges
as well as the ADP/Epinephrine Test Cartridges are sold in pack of 20 that cost $300 each.
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2.8.3

Helena—AggRAM Module and Analyzer
The Helena AggRAM device uses light transmittance to analyze platelet aggregation in

four channels at once and specialized software to graph the results. The four channels can run
tests for various dilutions of one patient’s blood or run 4 separate patient samples at the same
time.

The device links to the software and automatically calculates the slope, max %

aggregation, and time to reach max % aggregation. The lag phase is displayed on the computer
along with graphs and curves which can be printed out or saved for documentation. A database
exists for the storage of results and graphs for quality control purposes. This device assumes that
the patient is already taking clopidogrel but could potentially be modified by adding different
concentrations of the anticoagulant to the various cuvette samples. (22)
The run time for the AggRAM Module is about 3 minutes with a 45 minute incubation
time. 450 µL of whole blood is needed for each cuvette, but generally at least 900 µL is used
because one of the cuvettes will be used as a baseline with 100% coagulation. The procedure
begins forming the test sample by mixing the whole blood and the anticoagulant, sodium citrate.
This mixture is centrifuged for 10-15 minutes and then sits for 30 minutes before the test can be
performed. The baseline sample does not contain anticoagulant but was also centrifuged for 1015 minutes. During this time period a platelet count is performed so the platelets in each sample
can be standardized, usually to 250,000/mm3. To begin the test, ADP, collagen, and epinephrine
are added to all samples except the baseline sample along with a stir bar and then incubated for
1-3 minutes. The cuvettes are placed in the module and the light transmittance begins. (23)
A laser diode is used to conduct light transmittance detection. The change in absorbance
along with the increased light transmittance is measured as platelet aggregation occurs. The
percent of aggregation is calculated using the following equation:
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% 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 =

𝑶𝑶.𝑫𝑫.𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊 −𝑶𝑶.𝑫𝑫.𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎
𝑶𝑶.𝑫𝑫.𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊𝒊

∗ 𝟏𝟏𝟏𝟏𝟏𝟏

(2-1)

where O.D. is the optical density. The sample’s results can then be compared to the baseline
sample and stored graphs of patients that had normal
platelet aggregation.
The price of the device is listed as $7,995 and the
analyzer software costs $14,995.

The reagent kit

containing ADP, collagen, and epinephrine costs $116 and
accounts for 2 full tests. An additional cost must be
factored in for buying the silicon coated cuvettes and a
one-time cost for the magnetic stir bars.

2.8.4

Figure 2-6 Helena Laboratories AggRAM
Module and Analyzer (22)

Conclusions
After comparing the MCCRA System to its three main competitors, the analysis proves

that the system is a better product. Table 2-4 compares major features and prices of our device
against its three main competitors: Accumetrics’ VerifyNow System, Siemens’ PFA-100 System,
and Helena Laboratories’ AggRAM Module and Analyzer.
While all of the products have an error detection system, our device’s is more advanced
since each channel has a twin channel running a test on the same concentration. This feature is
very beneficial because it will allow errors to be easily displayed in the graphs that show the
results for the twin channels. If there is a discrepancy between the graphs, the discrepancy could
be accounted for by either a diode being broken or a channel being clogged or blocked. This
error detection will verify if the test has to be rerun.
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With a runtime of 5 minutes and an incubation period of 5 minutes, the MCCRA system
also has a faster or comparable turnaround than the other products. The system that has the next
fastest turnaround is Accumetrics’ VerifyNow System which completes its test in 3 minutes and
has an incubation period of 10 minutes. The product that has the longest turnaround time is
Helena Laboratories’ AggRAM Module, which is also the product that is used as our reference
concept in the Pugh Matrix seen in the Product Concepts section of this report. While the
device’s runtime is only 3 minutes, its incubation time is 45 minutes because the whole blood
sample needs to be centrifuged for 15 minutes and required to sit for 30 minutes before testing.
The testing procedure is very efficient. The MCCRA device uses the least amount of
whole blood, 550 µL. Our microfluidic chip has eight assay channels that test four inhibitor
concentrations so the patient’s resistance to clopidogrel can be assessed in one test rather than
two or three like other competing products. The procedure requires very little clean-up because
all of the reagents and sample are kept on the chip. This is similar to the test cartridges for the
PFA-100 System since all of the reagents are in this cartridge along with the blood once it is
added. The VerifyNow and AggRAM Systems differ. The VerifyNow uses a test tube to mix all
reagents with the blood before it is inserted into the machine and the AggRAM uses cuvettes
containing the reagents and blood that are placed in the device.
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Feature

MCCRA

VerifyNow

PFA-100

AggRAM

Runtime

5 minutes

3 minutes

5 minutes

3 minutes

Incubation Time

5 minutes

10 minutes

< 15 minutes

45 minutes

Sample Size

550 μL

2 mL

800 μL

900 μL

8 assay channels

1 assay channel

1 assay channel

4 assay channels

4 different assays

1 baseline channel

$6,000

$8,000

$15,000

$22,990

$100

$50

$30

$70

Testing procedure
System Cost
Cartridge/Test Cost

Up to 4 different assays

Table 2-4 Competitive Analysis

Finally, our product is cheaper than its competition. The box and software, which are
sold together as a package, have a list price of only $6,000 while the next cheapest device is
$8,000. Helena Laboratories’ AggRAM Module sells at a list price of $7,995 and its software
costs $14,995 which means our device and software is roughly $17,000 cheaper.

Our

microfluidic chip is sold for $100 while rival companies have chips or kits that range from $30 to
$70. We can justify that our chip is $100 because of the accuracy of the test. It is unlikely for
the test to be run more than once while tests for the VerifyNow and the PFA-100 Systems will
most likely have to be run more than once because the patient’s dosage will need to be adjusted
and re-tested.
2.9

Superior Product Concept
The MCCRA System has two main features that make it better than other competing

products: advanced error detection and testing multiple concentrations on one chip.
The error detection system in the device consists of two channels for each inhibitor
concentration. The duplicate channel will be located in a separate part of the channel bifurcation
system in order to show multiple potential problems. The potential errors these channels check
for are deformed channels from manufacturing complications and blockages in blood flow.
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Another reason to have multiple channels is to verify that the visible light diodes are working
properly. If the graphs from different channels for the same concentration vary, the diode could
be malfunctioning, indicating a technical problem as supposed to a real result with incorrect
clinical implications.
Testing multiple inhibitor concentrations at once on one chip is a very important
advantage. This saves the hospitals time and money by measuring the patient’s response to a
range of concentrations and determining an ‘effective dose’ regime rather than a one-time
parameter value. If a patient is in the hospital for only one test versus multiple, their hospital bed
will most likely be open in a shorter amount of time which keeps the influx of patients for
hospitals high and the hospital can make more money. Insurance companies and patients will
also save money because they will not have to pay for multiple tests. The MCCRA System is
creating a phenotype for the patient by testing various ranges of inhibition over a five minute
time interval. It is superior to the competing systems because it does not just measure the
patient’s response at a single point. The MCCRA System eliminates the need for any guess and
check procedures and allows for one single test, instead of two to three trials like its leading
competitors.
The price of the system is also very comparable or lower than other competing products’
prices.
2.10 Other Important Considerations
Safety is always an important consideration when running a company and producing a
product. It is important for the product to meet the standards of the industry while also keeping
the manufacturing floor safe for employees.
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Material Safety Data Sheets (MSDS) for PDMS, collagen, MRS 2395, ADP, acetone, and
isopropanol have been attached in the Appendix since all of these materials and reagents are used
daily in our facility. Among the advantages of our process is the fact that there are no harsh or
particularly corrosive or reactive chemical in use, both minimizing the risk to employees and the
environmental impact of an accident.
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Part 3 Feasibility Stage
Process Overview

3.1

3.1.1

Chip Diagram

Figure 3-1 To-scale representation of the microfluidic chip (draw in CAD).
This image is what was used to pattern the photoresist mask used to create the PDMS chip.

Figure 3-1 is a CAD drawing of our microfluidic chip design. Point A is the location at
which the patient’s blood sample is injected onto the chip before testing.

Point B is the

bifurcation pattern used to create 8 channels that are equal in all dimensions, and arranged so that
the flow through each of the eight channels is equivalent. At Point C, immediately following the
bifurcation, the channels straighten out and this is where MRS 2395 is deposited. Point D is
where the mixing section for the blood/MRS 2395 combination, including 10 turns and a series
of grooves in the channels in order to make sure complete mixing occurs before reaching the
next reagent. Point E is another straight area in the channels where ADP is deposited. At Point
F, mixing is achieved for the blood/MRS 2395/ADP combination, again implementing 10 turns
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and a series of grooves in the channel. The final straight section of the channels where collagen
is deposited occurs at Point G. This is where clot formation will occur and light transmittance
readings through the channel will be taken. Point H starts the reverse bifurcation of the eight
channels back down to one to exit into the waste reservoir. This design is used in order for the
blood to be pulled through the channels by the vacuum at identical flow rates, since no channel
will have increased force applied due to its proximity to the vacuum. The waste reservoir is
placed at Point I. The volume of this reservoir is approximately 1500 mL, which is more than 3
times the amount of space required to hold the blood sample. By providing sufficient volume in
the reservoir to hold the entire sample, the blood will never leave the chip and enter into the
device. Also, this should allow for enough space between the vacuum and the exit channel to
make sure that none of the blood is sucked into the vacuum. This figure is the representation of
the chip as it was fabricated to be used in lab tests (with the vacuum puncturing at the back
center location of the reservoir). The scaled up manufacturing design, however, has the waste
reservoir wrapping around one side of the chip and the vacuum puncturing the PDMS at the end
of this section in order to further prevent the splattering of blood onto the vacuum.
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3.1.2

Process Flowsheet
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3.1.3

Flow through the Microfluidic Chip

3.1.3.1 Bifurcation
The patient’s blood sample is injected into the chip at a
designated location (See Figure 3-2). From this point, a single

BLOOD
INSERTION
POINT

channel is branched into two equally sized channels. Each of
these channels is then also divided in half. This is repeated so
that there is a total of eight channels that are equivalent both in
dimension and spacing (See Figure 3-2). For a more detailed
Figure 3-2 Bifurcation
Depiction of the bifurcation of channels at
the beginning of the chip in order to evenly
divide the entry stream into eight streams.
The point at which the blood is inserted in
relation to the bifurcation is indicated.

description see Section 3.2.3.
3.1.3.2 Addition of MRS 2395
Once the blood has been equally divided into eight

separate channels, it is flowed over dry MRS 2395. Each pair of channels has a different amount
of MRS 2395. The four amounts of MRS 2395 used are 0 µg, 0.395 µg, 3.95 µg, and 39.5 µg.
Having varying amounts of the compound allows for four sets of data, each corresponding to a
different level of MRS 2395. Also, by having two streams contain each concentration, there is
an automatic error detection system since the two values
for each concentration can be compared for accuracy.
3.1.3.3 Mixing
After the blood has passed over the MRS 2395, it
passes through a mixing section. In this part of the
channel, the pathway turns 180° twenty different times
(after each 0.05 cm length of channel) for a total of 20
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Figure 3-3 Three dimensional depiction of a
section of one of the mixing portions of a
channel. In this figure, there are three 180°
channel bends. In each of the actual mixing
sections on the chip there are 10 bends. The red
arrows indicate the direction of blood flow.

full turns in order to aid in the mixing of the blood and the MRS 2395 (See Figure 3-3). In order
to ensure total mixing, there are also grooves built into the top of the channels (See Figure 3-4).

250 µm

235 µm

90°

36 µm

45°
60 µm

90°

90 µm

45°
235 µm
Figure 3-4 Three-dimensional depiction a section of mixing channel with grooves. (Not drawn to scale)
Note: this is a picture of the PDMS channel when fabricated, however, when joined with the glass surface, the PDMS is flipped
upside down, and the grooves will be above the flow of the blood.

3.1.3.4 Addition of ADP
After mixing with the MRS 2395, the blood flows over a region containing an ADP
deposit. The amount of ADP in each channel is 3.95 µg (equal amount in all eight channels).
Following the same mixing mechanism as before, the blood containing MRS 2395 is mixed fully
with the ADP.
3.1.3.5 Collagen and Light Transmittance
The blood containing MRS 2395 and ADP then flows over a surface coated with a
collagen deposit of 4 nL (equal amount in all eight channels). As it passes over this region, the
collagen activates the formation of a blood clot (See Section 2.1). Once the blood starts passing
over the collagen, the MCCRA device will begin taking light transmittance readings (See Section
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3.3).

The amount of clotting that

occurs will depend on the resistance
level of the patient, as well as the
amount of MRS 2395 that was
added to each channel. (See Figure
3-5)
3.1.3.6 Waste Disposal
Once the blood has passed
over

the

collagen,

it

proceeds

through a reverse bifurcation setup and
into the waste reservoir. The second
bifurcation assures that the blood will

Figure 3-5 3-D depiction of the collagen section of one of the channels.
The red arrows indicate the flow of blood through the channel. A blood
clot forms on the collagen and a white LED located in the MCCRA device
above this section of the channel shines on the clot. The magnitude of
the transmission through the clot is measured by a light sensor located in
the device, below the chip.

be pulled at the same flow rate in each of the eight channels by eliminating a variance due to
proximity to the vacuum. The waste reservoir is designed so that there is enough space to hold
1.5 mL of blood (approximately three times the 550 µL of sample that is used). By making the
reservoir sufficiently large, all of the blood will be contained on the chip at all times, i.e. at no
point in the testing process will blood reach the vacuum or any other component of the box.
After the test is completed, the chip can be removed and disposed of without needed excessive
cleaning of the box. Also, the vacuum is connected by a puncture into the top of the chip
(through the PDMS layer) into the waste reservoir. By having the vacuum pulling from above
the waste reservoir, the blood that settles into the bottom of the reservoir will be far enough from
the vacuum that it will not be pulled up into it. (See Figure 3-6)
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TOP VIEW
vacuum
Channels
Channels

vacuum
vacuum
PDMS
Waste Reservoir
SIDE VIEW

3.1.4

Figure 3-6 Depiction of the waste reservoir with respect to
the channels and vacuum location on the chip.
The light blue lines represent the outline of the waste
reservoir, the black lines represent the outline of PDMS, the
gray area represents the area of the chip where the channels
are located, the black arrows show the direction that the
vacuum is pulling, and the red arrow shows the direction of
blood flow out of the channels and into the waste reservoir.

Process Conditions and Reagent Volume
This section explains the unapparent process embedded between the blood entering the

machine and read-out from the display. Shortly after 550 µL of blood enters the micro-channels
of the chip, which is controlled at 37oC by a temperature reservoir within the box (See Box
Design), it splits into 8 identical streams through graduated bifurcation. Each stream first
encounters the MRS 2395 matrix and undergoes dissolution and mixing. Downstream to MRS
2395, the blood flow undergoes ADP-carbohydrate dissolution and mixing processes before
flowing though collagen, where platelet aggregation is detected. The 8 streams are grouped into
2 identical sets of 4 streams. In either set, each steam dissolves a different amount of MRS 2395
to achieve 0X, 0.1X, 1X, and 10X the IC50 of 3.6µM. (24) Although the targeted concentrations
of MRS 2395 are set and ready, the calculation that is needed to determine the amount of MRS
2395 deposition on the micro-channel to achieve such concentrations is rather involved. Table
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3-1 gives a summary of the amount of depositions and detailed computation can be found in
Appendix 7.2.

Reagent

Amt. in stream Amt. deposit on chip

Whole Blood

550 µL

MRS 2395 (0xIC50, 2 streams)

0

MRS 2395 (0.1xIC50, 2 streams) 0.36uM

0
0.00057 mg

MRS 2395 (1xIC50)

3.6uM

0.0057 mg

MRS 2395 (10xIC50)

36uM

0.057 mg

ADP (all 8 streams)

3.6uM

0.0057 mg

Table 3-1 Reagent target concentration in 8 flowing streams and amount (mg) for deposition on
micro-channels.

3.2

3.2.1

Detailed Chip Design
Chip Fabrication

3.2.1.1 Manufacturing Considerations
The microfluidic chip for use in our point-of-care device will be manufactured in our own
facilities. It was initially proposed that an outside company could be contracted to fabricate the
chips, partly due to the large cost associated with constructing a fabrication facility. However, it
was agreed that the intellectual property inherent in our device should not be put at risk by
outsourcing the process.
As mentioned in an earlier chapter, the chip will be constructed of two layers: a bottom
glass layer and a top PDMS layer. This patterned design must be present on the PDMS layer,
whereas the deposition of the various reagents must occur on the glass layer. To pattern the
PDMS, photolithography and soft lithography were both found as options. Advantages and
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disadvantages were associated with both ways, and in the end a soft lithography technique
known as replica molding was decided upon for use. Another issue that needed to be addressed
was the method of deposition of the MRS 2395, ADP and bovine collagen. Use of a robotic pin
tool was considered, as well as an inkjet dispenser for delivery. Since three reagents need to be
deposited per channel and eight channels are present on one chip, 24 depositions must occur per
chip. Therefore, the speed of delivery in each system was contrasted to insure that the goal of
4,000 chips manufactured per day could be attained. After considering a number of attributes,
including price, a robotic pin tool was found to be suitable for our purposes. Finally, equipment
including a curing oven, plasma oxidizer, and UV light emitter were needed for curing of the
PDMS top layer, sealing of the two layers and sterilization of the device, respectively.
3.2.1.2 Patterning of PDMS Layer
The top layer of the microfluidic chip will be constructed with the elastomer known
polydimethylsiloxane, or simply PDMS. This material was decided upon to form the foundation
of the device because of its advantageous molding capabilities. Initially present in the form of a
base and curing agent, a mixture of the two parts can be patterned with a certain design using one
of any number of different methods: microcontact printing (µCP), replica molding (REM),
microtransfer molding (µTM), micromolding in capillaries (MIMIC), solvent-assisted
micromolding (SAMIM), and photolithographic patterning of photosensitive PDMS. All of these
methods have advantages and disadvantages in their application to fabrication of our device.
Photolithography methods for fabrication of our device were first explored.
Microfabrication in the electronics industry almost exclusively uses some form of
photolithography due to its ability to use a single photomask for the mass-production of thin film
patterned devices. Because of the rather large goal of one million chips to be produced per year,
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a parallel process that could yield a high net output of devices per day while maintaining a high
fidelity of the product was a desirable trait. Since photolithography has been used to great
success in the electronics industry, a process that incorporated such was sought. The search
resulted in the finding of a technique for making the PDMS layer of the device photosensitive,
thus making it susceptible to patterning by ultraviolet light. The method called for the inclusion
of benzophenone in the initial mixture of PDMS base and curing agent. Amounts of
benzophenone to be included could range from 0.1%-15% (v:v). The addition of this compound
led to the formation of a benzophenone radical when irradiated with UV light (λ < 365 nm),
which abstracts a hydrogen atom from any suitable hydrogen donor. These radicals react with the
silicon hydride groups present in the PDMS crosslinkers and prevent them from undergoing the
traditional crosslinking reaction with the PDMS monomer. (25) Therefore, regions of the chip
irradiated with UV light will be prevented from curing when heated, and the PDMS in these
areas can be washed away with an organic developer (solution). In this case, the photoinitiator is
termed a positive resist. The positive acting nature of benzophenone makes for a simplified
fabrication process for the microfluidic chips. In addition, features on the order of a few microns
can be easily fabricated using this method. Although the use of photoPDMS seemed like a viable
option, a number of concerns were brought to our attention. First, the process was not entirely
proven. The idea for the use of benzophenone as a photoinitiator and subsequent experimentation
was carried out by a research group at the University of Cincinnati. While the results appeared
promising and a number of papers have been published regarding photoPDMS, there is no
industrial documentation showing the successful implementation of this idea into the fabrication
of any elastomeric (PDMS) device. Furthermore, a number of the steps involved in treating the
soluble portion of the surface might not be advisable. In the description given, the exposed
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region was developed by dipping in a toluene solvent for about 5 seconds. The use of this
organic solvent or any comparable solvent used as developer was advised against due to safety
issues and FDA approval issues. (26) Consequently, another way to pattern the PDMS into our
given design was required.
The field of soft lithography evolved from the need to produce desired patterns utilizing
elastomers as a mold or stamp, as well as the requirements for a fabrication process that was low
in cost, easy to learn, and easy to adapt to given set of circumstances. It possesses several
advantages over conventional photolithography: soft lithography can utilize not just photoresists
as a patterning surface but many different kinds of polymers, biological macromolecules and
beads, it can pattern both planar and nonplanar surfaces in all three dimensions, and it can pattern
features at about an order of magnitude smaller than photolithography. (27) A major key to soft
lithography is the use of a single master to create multiple molds that can then be used to
fabricate a large amount of devices. The master is normally made using conventional
photolithography: resist is spun onto a silicon wafer, the image is imprinted on via irradiation
with UV light or using e-beam lithography, the wafer developed and the pattern made. A PDMS
mold is then made from this master, which in turn serves as the cast for the further fabrication of
patterned PDMS layers that are used for any number of microfluidic chip devices. Elastomers are
used as the material to make molds due to their ability to make conformal contact with surfaces
over relatively large areas and the ease with which patterned layers can be released from the
surface of such a mold. In addition to the advantageous qualities of PDMS such as low
interfacial free energy, good thermal and chemical stability, and optical transparency to
wavelengths as low as 300 nm, one of the most beneficial qualities it possesses is its durability.
According to literature, PDMS molds were used up to fifty times without a noticeable decline in
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performance. (27) For all of its positives, a number of potential issues exist that might become
problematic in the future. First, the PDMS has been shown to shrink slightly upon curing. This
would lead to a distorted patterned layer. (28) Also, due to the elasticity and thermal expansion of
PDMS, fabrication of multiple layers or layers with nanoscale features might be difficult because
of the trouble in accurate patterning across large swaths of area. Finally, the suppleness of the
PDMS restricts the patterning of extreme aspect ratio features (very high or very low
height/length) because of the risk of deformation. Despite some of these concerns, the usefulness
and applicability of soft lithography to the fabrication of our microfluidic chip seemed too
beneficial to ignore. Compared to traditional photolithography processes explored, soft
lithography allowed for the production of many chips in parallel while retaining a simplistic
design process. However, a number of different soft lithography fabrication methods exist. Each
methodology differs in its fabrication of the mold that forms the template for the patterned layer.
Thus, a detailed analysis of each was required to decide which fit the manufacturing of our
device appropriately.
The first type of soft lithography method analyzed is termed microcontact printing (µCP).
It is based on a fundamentally basic concept: the design on the surface of a PDMS stamp is
exploited to form patterns of self-assembled monolayers on the surface of a substrate through
physical contact.

(27)

Self assembly, which describes the change from a disordered state of

material to an ordered state due to local, noncovalent interactions and not under any external
pressures, is unique to microcontact printing. (29) In brief, the molecules of the system will keep
changing states until the state with the lowest energy is found (chemical equilibrium).
Furthermore the system will be at thermal equilibrium, which means that the system will
spontaneously recover from any defects that might occur. Fabrication of a layer entails the
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coating of a PDMS mold with a ligand (in the form Y(CH 2 ) n X, where the X head group is
commonly a methyl group and the Y anchoring group is sulfur, phosphate, etc.), which then
comes in physical contact with the substrate. (27) Afterwards, etching or further deposition may
occur to finish patterning the layer. This technique has the possibility of assisting us in creating
the herringbone structure needed for proper mixing. However, the process appears too tedious
and not amendable to a manufacturing process that demands high rates of production. Therefore,
this idea was not investigated further.
The next method explored was microtransfer molding (µTM). In this method, a slim layer
of liquid prepolymer (base plus curing agent) is applied to the patterned surface of a PDMS mold
and the excess liquid is removed through any number of means. The combination of the
prepolymer and curing agent within the mold is then put in contact with the desired substrate,
when upon curing of the elastomer commences. After curing with UV light or heat, the result is a
patterned layer of polymer that is left on top of the substrate. These patterned microstructures
then may be used as masks to control the deposition or etching of the exposed substrate, or more
simply as a mold for creation of other patterned layers. (30) The method can use a wide array of
polymers as the mold materials, and fabrication of large structures (about 3 cm2) can be
completed in a small amount of time. These attributes seem to fit the requirements we are
seeking in a fabrication scheme. However, two problems become apparent upon inspection. The
first is relatively straightforward: our chip currently has dimensions of 4 cm by 6 cm and an area
of 24 cm2, whereas the maximum area of a device found in literature was only about 3 cm2.
Second, a layering problem exists if this fabrication mode is used. Our plans call for the bottom
layer of our device to be a glass substrate, onto which the patterned layer of PDMS will make
contact with. The channels and other patterned features must be present in this interface.
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However, the product of microtransfer molding leads to a patterned surface not at the interface,
but at the opposite side of the polymer layer. Although sealing of this side to a glass substrate
coupled with subsequent removal of the initial substrate is possible, it seems like an unnecessary
step. The use of a physical mold, though, seems to be a viable alternative to photolithography
because of the ability to produce identical molds in high volume and combine them on one
surface to fabricate many PDMS layers in parallel.
Micromolding in capillaries (MIMIC) is another soft lithography technique that was
considered. In MIMIC, a mold composed of an elastomeric material is placed against a desired
substrate. Channels intentionally formed between the mold and the substrate are filled with a low
viscosity prepolymer by capillary action. The polymer is cured and the mold is separated from
the device to yield a substrate layer with microstructures on its surface. (31) Again the range of
material compatible with this technique is very broad, spanning UV- and thermal prepolymers to
biological macromolecules. Additionally, the minimum feature size extends down to as low as
hundreds of nanometers, far exceeding the spatial requirements of our device. However, the
amount of time to diffuse through the channels by capillary action inhibits this technique by not
allowing patterned layers to be fabricated fast enough to comply with the desired throughput.
Also, relying on capillary action to fill the mold’s channels might introduce significant error into
fabrication and might lead to channel-to-channel variability between chips, and even between
different channels on a chip. Finally, the amount of PDMS used would have to be large because
the mold must have the channel features protruding from its surfaces, meaning capillary action
would have to account for the deposition of most of the elastomer on the chip. Besides
introducing further potential error and variability in fabrication due to the amount of fluid needed
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to be moved, the patterned side would again be on the opposite side of the initial substratePDMS interface, leading to more unnecessary processing steps.
A fourth technique abiding by the tenets of soft lithography is solvent-assisted
micromolding (SAMIM). SAMIM generates a pattern in the surface of a material using a good
solvent that perturbs the material enough so as to make it pliable, but not to the extent of
affecting the composition or stability of the mold. SAMIM proceeds by taking a PDMS mold and
wetting its surface with the chosen solvent. (32) The mold is then placed onto the surface of the
substrate. A thin layer of the substrate material is dissolved by the solvent, and this layer
conforms to the shape of the mold. When the PDMS mold is released from the surface, the
solvent evaporates and substrate solidifies. The surface of the substrate is now complementary to
that of the surface of the mold. Solvent-assisted micromolding has been shown to work with a
wide variety of materials, including organic polymers such as PDMS. Observations of submicron
features patterned by this method showed very little defects. In the context of our device, a solid
layer of PDMS would have to be made and then the PDMS mold plus solvent applied to pattern
the surface. This patterning method fulfilled requirements relating to compatibility with PDMS,
feature size and adaptability to a large-scale manufacturing scheme.
The last soft lithography method explored was termed replica molding (REM). The most
basic of the subset of micromolding techniques, it allows the transfer of the information present
in a mold to a layer of polymer by simple conformation to the template’s shape. (33) Compared to
other methods, large amounts of polymer are used in REM. The accuracy of information transfer
from the mold to the surface depends on noncovalent interactions occurring within the polymer,
the nature of the mold surface, and the speed at which the mold is filled with the polymer.
However, the beauty of the process lies in its ability to create a patterned structure
- 43 -

complementary to that of the mold in just one step. The benefits this imparts to our
manufacturing process are tremendous: since multiple molds can potentially be grouped together
on one surface, many PDMS layers can be constructed in parallel. Furthermore, one master with
the desired image translates into many molds, and the molds are made in simple and costeffective way. Feature sizes with a resolution smaller than 10 nanometers were observed in
laboratory experiments, which far exceed that needed on our microfluidic chip. (34) In addition, it
has been shown that replication from a single master can proceed more than ten times without
significant degradation in the quality of the patterned layer or mold.

(27)

Combined with the

benefits of simple, straightforward micromolding, the durability of the PDMS molds makes
replica molding the easiest soft lithography technique to transfer from benchtop to large-scale
manufacturing.
After an exhaustive study of all options, it was agreed that our manufacturing scheme
would take from the principles underlying replica molding. This micromolding technique
satisfied our requirements of low cost, ease of production and ability to produce in high volume.
However, the process would have to be custom fit to our needs. To achieve a chip production
between one thousand to four thousand chips produced per day (depending on which production
year considered), many hundred molds needed to be present on each manifold. It was decided
that a few masters would be created, which would serve as the templates for the molds. The
masters would be created from normal lithography means. Our design called for channels of
several different lengths, with heights of 60 micrometers and widths between 250 micrometers
and 1000 micrometers. The other major feature on the chip is the waste reservoir, which has
dimensions of 1 centimeter by 2 centimeter by 0.5 centimeter. All of these features are far above
the feature size limit of photolithography, and can therefore be fabricated with high accuracy.
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With a silicon wafer as a substrate, master creation would
begin by applying positive photoresist onto the substrate to
give a resist thickness of approximately 250 micrometers.
After exposure to UV light under the direction of a chrome
mask that only permits passage of light in the areas that
correspond to the channels and reservoir, the master is baked
to cure the unexposed resist while the exposed resist is washed
with an organic solvent (developer). The result is a substrate
with 250 micrometer deep channels and reservoirs in positions
corresponding to those on our chip. However, all of the
channels need to be 60 micrometers in depth and have a
herringbone structure that is recessed 36 micrometers into the
channel floor. Therefore, a second deposition of approximately
190 micrometers of positive photoresist is needed. The master
is then exposed to UV light according to the layout of another
mask, which will have openings for the herringbone structure
in the proper channels. After curing and developing
the master, channels of 60 microns and the mixing
features of 36 microns are patterned. Finally, the
master is silanized to give the patterned surface a
hydrophobic nature, which reduces any adverse
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Figure 3-7 The accompanying diagram shows the
processing of the master that will be used to
construct the PDMS molds.
A silicon wafer (grey) with oxide (green)
deposited on it is spin-coated with a positive
resist [1]. The resist is patterned to give 250
micron deep wells [2]. Another layer of positive
resist is spin-coated onto the wafer [3]. Finally,
the resist is again exposed to UV light to fabricate
the herringbone structure at the bottom of the
channels.

reactions or absorption. An outside microfabrication facility would be contracted to for master
creation because of the large cost associated with buying the necessary photolithography
machinery that would only be operated sparingly.
When the master was finished, PDMS molds complementary to the surface pattern of the
master could be made. As mentioned prior, parallel production of the PDMS layer of the
microfluidic chip called for large manifolds containing hundreds of molds. PDMS was chosen as
the mold material because of several reasons. First, PDMS is durable enough to withstand
repeated use as a stamp and not become structurally compromised. Studies showed highly
accurate pattern transfer by PDMS stamps after more than ten uses. (34) Since our molds will only
be used once or twice per day, their lifetime could be on the order of a month or two. Also,
polymers patterned against the PDMS mold won’t adhere or chemically react to the mold’s
surface. The only concern is that the aspect ratios of the channel features (the features would
extrude from the mold since its pattern is complementary to that of the master and final PDMS
layer) fit into the range allowed for PDMS molding. Specifically, the channels all have aspect
ratios (a ratio of height/width) that fall somewhere between 0.06 and 0.24, while the reservoir
has an aspect ratio of about 0.125. One study found that aspect ratios of features should fall
between 0.2 and 2 to obtain defect-free molds. (35) Since our features fall on the low end of that
scale, the integrity of the pattern of our PDMS molds could be in question. However, small
changes to our chip design could be undertaken during the initial startup of our manufacturing to
correct any problems with information transfer by our mold. It was decided that production of
the molds and manifolds would be outsourced because of the cost of excess equipment necessary
for their construction, as well as the only occasional need for a new manifold (about once every
month or two, depending on the actual durability of the PDMS mold). The manifolds will be
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filled with PDMS and thermally cured, giving the desired PDMS block with channels and
reservoir ready to be sealed with the bottom layer. With a successful way to fabricate the PDMS
layer within our manufacturing scheme found, the deposition of reagents is considered.
Figure 3-8 The accompanying diagram shows the
fabrication of the PDMS layer from its respective mold.
The mixture of PDMS base and curing agent is applied to
the PDMS mold at a volume consistent with the desired
chip features [1]. The mold is then cured for 2 hours at
80°C [2]. Due to low interfacial energy, the PDMS layer is
easily plied away from the mold [3]. The PDMS mold is
now free to be used again, while the PDMS layer and
glass substrate are surface treated and subsequently
bonded together [4].
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3.2.1.3

Deposition of Reagents on Glass Substrate
To successfully carry out an assay of the degree of clopidogrel resistance expressed by

the patient’s blood, three reagents must be present on the chip. The first is collagen, which acts
as a substrate for the deposition of platelets and as a secondary activator. ADP, which acts to
stimulate platelet aggregation, also needs to be deposited. Finally, the platelet aggregation
inhibitor MRS 2395 is deposited on chip in different concentrations. Since the volumes to
deposit will be in the tens to hundreds of nanoliters range, normal liquid delivery systems will
not suffice. Technologies that have evolved from drug discovery allow the addition of nanoliter
to picoliter amounts of reagent in order to test large libraries for compounds that inhibit a
biological target. Two fluid delivery systems seem to be candidates for use in the manufacturing
of the microfluidic chip: inkjet fluid handling and robotic pin tool delivery. The mechanics
behind each system and the ability to fit our requirements were explored.
3.2.1.4

Inkjet Fluid Handling System
A ubiquitous technology vital to the operation of the personal computer printer, inkjet

fluid handling is a valuable technology because of its ability to deliver very small volumes of
reagent. Fluid is delivered in two distinct modes: continuous and demand. In continuous mode,
fluid flows through a small opening while an electrochemical device creates pressure oscillations
that cause the fluid to break into droplets of roughly equal size. Once past this opening,
electrostatic charge is induced in the drops by the action of an electric field. Another electric
field is then used to direct the drops toward a surface. Using this mode, droplets ranging from 10
ficoliters to 0.5 microliters are delivered between 80-100 times per second. (36) If the machine is
run in demand mode, a potential across a layer of piezoelectric material leads to the formation of
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a pressure change in the fluid. The result is the discharge of a single droplet to the desired
substrate. Therefore, this mode is much more deliberate in its application.
Our process required deposition volumes somewhere in low nanoliter range, which is
easily achieved by this device. Additionally, our goal of 4,000 chips manufactured per day meant
that the time to deposit the reagent per channel should be as fast as possible. The most optimistic
estimate of deposition time was found to be about one site every 1-2 seconds. To accomplish our
manufacturing goals, though, much more than that was needed. Not only are there 8 sites per
chip, but three different reagents needed to be deposited in eight places, adding up to a total of
twenty-four spots. Using the optimistic deposition rate of five to ten sites per second, it would
take about two seconds to deposit one reagent on a chip. The total time to complete deposition on
one chip would probably be between six to eight seconds. While this is not exactly detrimental to
the manufacturing process, there is an obvious need for multiple printheads to realize our daily
manufacturing goal. Initial pricing of an inkjet fluid handling system approached almost
$200,000. Assuming the prior rate of deposition, we would need three separate systems to
complete fabrication of 4,000 chips per day. To pay almost half of one million dollars just on the
fluid delivery system seemed like an exorbitant cost. Therefore, analysis of inkjet fluid handling
systems was halted and the potential of using a robotic pin tool for liquid transfer was
investigated.
3.2.1.5

Robotic Pin Tool
Known for its use in the screening of compound libraries in drug discovery, robotic pin

tools are commonly used in the transfer of small reagent volumes between a stock solution and a
substrate. Fluid is transferred by simply adhering onto the pin tool by surface tension and then
coming in contact with the substrate surface. The pins that actually transfer the liquid are arrayed
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in a head that contains a certain amount of pins. For our deposition, a standard 384 pin tool head
could be used. This gives about a 4.5 millimeter space between pins, which should insure that we
can deposit the reagent accurately. The pins that will be used are hydrophobic/lipophobic coated,
which discourages reagent adsorption. 4 nanoliter, 10 nanoliter and 20 nanoliter pins would be
used for the deposition of collagen, MRS 2395 and ADP, respectively.
When a robotic pin tool system with these specifications was priced, the cost to
implement one was found to be less than half that of the inkjet fluid delivery system. Specifically,
a mounting plate for the device cost $375, the pin tool head cost $2,521, the pin tools themselves
cost either $9 or $11 per pin depending on the delivery volume, and the robotic station cost
$20,000 (all prices were of Beckman equipment). The total here comes to about $30,000,
assuming a large amount of pin tools are bought. Although the price may not be 100% accurate,
the money invested in such a system is considerably less than inkjet system and allows us to
invest in multiple robotic pin tool systems to increase parallel production and throughput of the
microfluidic devices. No concrete evidence was found regarding deposition rates, but a value of
3 seconds per transfer was used. The robotic pin tool system from Beckman comes customizable,
which is useful because of the need for adaption to a manufacturing line.
3.2.1.6

Reagent Loading Scheme
Contrasted against each other, the decision to use the robotic pin tool for deposition of the

reagents was a straightforward one. First, the robotic pin tool could deliver all eight deliveries of
the same reagent in one deposition. Although some calibration of the system and alteration of the
chip design might have to occur, the spacing should allow for 8 pins to be present on a pin head
and deliver the reagent to the desired position. The other main difference was the estimated cost
of the systems. With purchase costs differing by almost $400,000,
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the much lower cost

investment possible with the robotic pin tool system lends itself to the purchase of multiple
systems. This benefit helps us realize our goal of 4,000 chips fabricated per day, and allows for a
smaller expenditure on equipment if production was to increase in the future.
One of the only concerns with the deposition of our reagent is exactly how much will
evaporate. With such small volumes and large surface area to volume ratios, evaporation occurs
quite quickly after the droplets are applied to a substrate. In literature, an estimate of 1 nanoliter
of aqueous solution will evaporate in approximately thirty seconds. (37) Therefore, the amount of
time it takes to deposit the reagents and then seal the PDMS and glass substrate is crucial to the
extent of evaporation that will occur. Additional steps can be taken to reduce evaporation of the
reagents. Including viscous substances, such as glycerol, in the reagent mixture is shown to
reduce evaporation while not reacting with the deposited compounds. The temperature can also
be maintained low enough such that the vapor pressures of the compounds are decreased, leading
to less spontaneous evaporation. Finally, the manifolds can be temporarily sealed following
deposition to further reduce any loss of reagent. It will probably take a combination of the
following precautions to combat evaporation and maintain the reagent’s concentration on chip.
The problem will have to be addressed with appropriate design changes during the first year of
design.
3.2.1.7

Curing Oven
Once the PDMS is deposited into its mold, the prepolymer and curing agent need to be

allowed to set. This process crosslinks the polymer and forms the basis for its solid support. Our
recipe calls for the PDMS to be cured for two hours at 80°C. Initial plans required two batches of
2,000 PDMS molds each. Using a rough estimate of actually area of 2,000 PDMS molds plus
more area in between the molds and on the edges, the size of the manifold was determined to be
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about 55 ft2. After contacting a number of companies, two ovens were found. The first oven
found was from Engineering Production Systems. For an inside chamber area of approximately
75 ft2, and with outside dimensions of 6 ft x 5.5 ft x 7 ft, one Composite Curing Oven from EPS
would cost us about $50,000. The oven is fairly high technology, especially considering our very
basic needs and high tolerance. Another oven, from Wisconsin Oven Corporation, was priced at
$22,400. The inside area of this oven was about 60 ft2, which is slightly smaller than the EPS
oven but should accommodate our needed size. Since both are equivalents in the eyes of our
process, the SWN 610-6 oven from Wisconsin Oven Corporation was chosen for its significantly
lower price. (38)
3.2.1.8 Plasma Oxidizer
To irreversibility bond the two layers together, the adjoining surfaces need to be treated
by plasma oxidation. This is accomplished by a plasma oxidizer, which is a machine that
converts gas into ions and directs them at a substrate. PDMS is a repeating polymer consisting of
–O–Si(CH 3 )– subunits. However, introducing the surface of PDMS to air plasma leads to the
replacement of the silane moiety with a silanol group. When this polar surface comes in contact
with another substrate, the hydroxyl groups of the silanol condense with hydroxyl, carboxylic or
ketone groups from the substrate to form a seal. (39) The bonding between the glass substrate and
PDMS layer in our device yields an inorganic ester bond (Si–O–Si) concomitant on the loss of
water. The covalent relationship between the surfaces is manifested by the irreversible bond that
forms between both surfaces. A surface treatment machine from Electric-Technic Products
accomplishes this task. The BD-80 Corona Treater, priced at about $5,000 per unit, is capable of
treating one surface with air plasma within the desired 1 minute window. An adaptor kit made it
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possible for the machine to be hooked up to a conveyor belt for repeated surface treatment of
many layers. Thus, it was decided that the BD-80 Corona Treater would be purchased.
3.2.1.9 UV Sterilization
As a precaution, it was advised by a number of consultants to sterilize the microfluidic
chip before storing it to insure no contamination issues arose. Therefore, after packaging into
vacuum-sealed plastic bags, it was decided the device would pass under an array UV lamps to
insure a sterilized environment in the chip. A lamp from Cole-Parmer, the UV Germicidal Lamp
EW-97505-05, was chosen for the task. An array of 5 lamps would be put on the end of each
production line, and the packages would simply pass under them on their way to refrigerator
storage.

3.2.2

Chip Manufacture

3.2.2.1 Microfluidic Chip Recipe
Thirty minutes prior to the beginning of each day, PDMS prepolymer will be mixed with
viscous curing agent in a large tank. Needing 17.49 millilters of total PDMS in each chip,
assuming less than 1% shrinkage, and abiding by the 10:1 (v:v) ratio of base to curing agent, the
tank will contain about 70 L of PDMS. It will be mixed with an impellor at low RPMs for
approximately 10 minutes.
Two manifolds containing 2,000 molds each will be used for the curing stage. Each
manifold will have two sets of valves with ten spouts each. These will deposit 17.49 mL into
each mold, taking approximately 20 minutes. Both manifolds will then be placed in the curing
oven. Currently, the curing time is estimated to be about two hours.
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As the PDMS layers are being cured, reagent stocks for each robotic pin tool system will
be prepared. 10 microliters of bovine collagen will be added to the refrigerated reagent store of
each robotic pin tool system. 30 microliters of 200 mM ADP will then be added to the reagent
storage of each robotic pin tool system. In vitro testing needs to be done to ascertain the amount
of MRS 2395 needed per chip, but an estimation of 20 microliters for the reagent store will be
used until then.
Deposition of collagen, ADP, and MRS on the glass substrate, which will be carried out
by three separate 384 well pin heads, should take 3 seconds each for alignment and actual
deposition of the liquid. This leads to a total deposition time of about nine seconds. Also, the
depositing of the reagents will all take place in a slightly cold environment to protect against
rapid evaporation.
When the curing bake of the PDMS is complete, the PDMS layer will be placed into
smaller manifolds containing 100 each. Robotic arms that have suction devices on their tips will
carry out transfer from a large manifold to a smaller one. The smaller manifolds will then
progress down the conveyor belt to meet with the finished glass substrate for surface treatment.
With two surface treatment devices working in parallel, the surface of the PDMS layer is
oxidized in one minute and then brought into contact with the glass substrate for another 30
seconds. With the microfluidic chips now in one manifold, the resulting 20-chip manifold is
placed onto the conveyor belt.
The devices are taken from the manifold via a robotic arm and placed in a packaging
machine that seals the chips in a plastic pouch. As the chips are transported to our freezer, they
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pass through a UV light array, which effectively sterilizes them for their lifetime in the
packaging.
As mentioned prior, the goal will be to fabricate approximately 4,000 chips per day,
which leads to a yearly manufacturing goal of one million microfluidic chips per year. In the first
two years of production though, the production goal will only need to be about 200 chips per day.
It is during this time that many chips will be needed for late-stage concept testing, quality
assurance and manufacturing process testing, and, most importantly, clinical trial testing for
FDA approval. Therefore, the majority of the chips produced during this time will not be for sale
but for testing (See Section 4.1).
3.2.2.2 Manufacturing Schedule
The full U.S. market is assumed to be 1.1 million chips per year, which is equal to the
number of Percutaneous Coronary Intervention (PCI) procedures performed in the United States
every year.

This number was used to determine the total market since the main use of the

MCCRA system is going to be before PCI procedures, when administration of clopidogrel is
required. Since there are other similar products already on the market, 100% market capture is
unrealistic (See Section 2.8). For the basis of calculations, it is assumed that the total market
captured by this product is 50%, or 550,000 chips per year.
Several factors are considered and several assumptions are made in the determination of
the number of chips that must be manufactured per day in order to meet this market capture goal.
The first assumption is that the manufacturing facility will operate 8 hours per day, 5 days per
week, and 50 weeks out of the year (250 days total). The number of chips needed for sale is
determined by Equation 3-1.
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𝟓𝟓𝟓𝟓𝟓𝟓,𝟎𝟎𝟎𝟎𝟎𝟎 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑 𝒚𝒚𝒚𝒚𝒚𝒚𝒚𝒚

𝟐𝟐𝟐𝟐𝟐𝟐 𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅 𝒐𝒐𝒐𝒐 𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐 𝒑𝒑𝒑𝒑𝒑𝒑 𝒚𝒚𝒚𝒚𝒚𝒚𝒚𝒚

= 𝟐𝟐𝟐𝟐𝟐𝟐𝟐𝟐 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑 𝒑𝒑𝒑𝒑𝒑𝒑 𝒅𝒅𝒅𝒅𝒅𝒅

(3-1)

The next assumption that is made is that approximately 25% of the chips that are made

during a manufacturing day will be used for quality assurance testing and cannot be counted
towards the chips to be sold. Therefore, in order to produce 2200 chips to be sold, 2934 chips
must actually be manufactured per day (See Equation 3-2).
𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎 𝒑𝒑𝒑𝒑𝒑𝒑 𝒅𝒅𝒅𝒅𝒅𝒅 ∗ 𝟕𝟕𝟕𝟕% = 𝟐𝟐𝟐𝟐𝟐𝟐𝟐𝟐 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑 𝒇𝒇𝒇𝒇𝒇𝒇 𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔

(3-2)

The final assumption that is made is that 25% of the chips that are manufactured will fail

due to defect. Therefore, in order to create 2934 successful chips, 3912 chips must be produced
(See Equation 3-3).
𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑 𝒑𝒑𝒑𝒑𝒑𝒑 𝒅𝒅𝒅𝒅𝒅𝒅 ∗ 𝟕𝟕𝟕𝟕% = 𝟐𝟐𝟐𝟐𝟐𝟐𝟐𝟐 𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑

(3-3)

(Note: for ease of calculations for manufacturing and financial analysis, this number was
rounded to 4,000 chips manufactured per day).
Based on the procedure for creating the chips, a manufacturing schedule was created (See
Figure 3-9).
0 :15 :30 :45 1

:15 :30 :45

2 :15 :30 :45 3

:15 :30 :45 4 :15 :30 :45 5

:15 :30 :45

6

:15 :30 :45

7

:15 :30 :45

mix/dep oven*

Deposition on glass substrate
Plasma/Join Layers
UV/Packaging

Deposition on glass substrate
Plasma/Join Layers
UV/Packaging

Figure 3-9 Schedule of a single day of operation for manufacture of the MCCRA chip. The numbers across the top
represent the hour of operation (in bold) and the breakdown of each hour into 15 minute increments. Assume that
hour 0 = the beginning of the day. Each colored band represents the length of time required for a specific step. Bands
separated by a space represent steps that occur simultaneously, but independent of each other (i.e. what is done in
one band does not have any effect on the other). Bands that are layered on top of each other also represent steps that
are occurring simultaneously, however the products of each step are used in the next, and therefore the completion of
one is dependent on the step represented by the band directly above it.
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This schedule is based on an eight hour day of manufacturing (time 0 =9:00 AM), assuming 30
minutes of time prior to operation for opening/setup of the facility and 45 minutes after
completion of manufacturing for cleanup/shutdown. The red box labeled “mix/dep” represents
the time required for the mixing and deposition of the PDMS onto the molds. Mixing takes
approximately ten minutes, and each deposition is estimated to take 3 seconds. Since the
deposition device has the capability of depositing 10 chips at once, the time for this step is
determined by Equation 3-4.
𝟒𝟒,𝟎𝟎𝟎𝟎𝟎𝟎 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄∗𝟑𝟑 𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔 𝒑𝒑𝒑𝒑𝒑𝒑 𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅
𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑 𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅

= 𝟐𝟐𝟐𝟐 𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎

(3-4)

Once the PDMS has been deposited, all 4,000 chips are put into the oven, for a total
curing time of 2 hours. Before going into the oven, the chips are placed onto 20-chip manifolds
(See Figure 3-10) for
easier

movement

35 cm

8.5 cm
1 cm

of

9.5 cm

chips

between

4 cm

steps.

The oven (Wisconsin

1
cm

35 cm

2.5 cm
1
cm

6 cm

Oven

Corporation,

Model:

SWN-610-6)

has internal dimensions
of 6’x10’x6’.

(40)

The

dimensions of the base

1 cm
1.5 cm

Figure 3-10 Manifold for chip manufacturing. The image to the left shows the manifold
layout, consisting of 20 total chips. The image to the right is an enlarged depiction of the
section of the manifold that is circled in red on the upper picture with dimensions labeled.
The white area represents the tray holding the chips and the blue rectangles represent the
chips themselves.

allow space for 3 manifolds by 4 manifolds (12 total manifolds). In order to fit all 200 manifolds,
17 shelves will be required for inside the oven, with the shelves situated approximately 10 cm
apart.
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While the PDMS molds are in the oven, deposition of the reagents onto the glass
substrates will be taking place. It is estimated that deposition will take 3 seconds per site. Since
there are 3 reagents in each of 8 channels, there is a total of 24 sites that need to be deposited on
each chip. This would results in a total of 80 hours of deposition if each site was deposited one
at a time. In order to cut down on this time, the deposition device will be equipped to deposit
each reagent in all eight channels at once. This will instead take 9 seconds per chip, for a total of
10 hours (see equation 3-5).
𝟑𝟑 𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔
𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓

∗

𝟑𝟑 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄

∗

𝟒𝟒,𝟎𝟎𝟎𝟎𝟎𝟎 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄
𝒅𝒅𝒅𝒅𝒅𝒅

= 𝟏𝟏𝟏𝟏 𝒉𝒉𝒉𝒉𝒉𝒉𝒉𝒉𝒉𝒉

(3-5)

Although this reduces the time required for deposition, 10 hours is still too long to fit into
a normal manufacturing day. Therefore, two deposition machines will run in parallel, reducing
the time required for deposition in half to 5 hours.
Once the PDMS layers have been removed from the oven, plasma oxidation and sealing
to the glass substrate can begin, using those substrates that have already been deposited. The
plasma oxidation/joining to glass substrate step for each manifold is estimated to take
approximately 2 minutes, then an additional 30 minutes to sit and finish the binding process.
Since each manifold can be oxidized while the previous begins the 30 minute resting step, the
total time required for this part of the process is estimated at 8 hours. Again, this step will be
divided in half and run simultaneously, reducing required time to 4 hours. Once the PDMS and
glass layers have been joined and have rested for 30 minutes, the UV sterilization and packaging
step can begin. The total estimated time for this part of the process is 3.5 hours (for half of the
chips, again run simultaneously).
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Once the packaging is complete, the chips are placed in a large refrigerator for storage
until needed for shipment or quality assurance testing. As shown in Figure 3-9, many of the
manufacturing steps can overlap, saving time, allowing for the manufacturing of 4,000 chips to
be completed during the 8 hour work day.
3.2.2.3 Manufacturing Facility Floor Plan
Taking into account the order of manufacturing as well as the general dimensions of the
required equipment, a basic floor plan was laid out (see figure 3-11).

Figure 3-11 Basic Floor plan schematic for the chip manufacturing facility.
It is based on the order of the steps in the process and the dimensions of the equipment to be use. Note: Size conversion
scale is located below the diagram to the left.
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3.2.3

Channel Dimensions
To ensure complete mixing and fully developed flow, bifurcation is used to split the inlet

stream into eight equal streams. Murray’s Law is followed to calculate the effective diameter
(𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒 ) of the parent channel (𝑟𝑟𝑝𝑝 ), or the channel that splits into two channels to form the
daughter channels (𝑟𝑟𝑑𝑑 ). Murray’s equation is shown below in Equation 3-6.
𝑟𝑟𝑝𝑝3 = 𝑟𝑟𝑑𝑑31 + 𝑟𝑟𝑑𝑑32 + ⋯ + 𝑟𝑟𝑑𝑑3𝑛𝑛 = 2 ∗ 𝑟𝑟𝑑𝑑3

(3-6)

The path-length (𝑙𝑙) of each branch before the next separation should five to six times the
effective diameter of the micro-channel.
(3-7)

𝒍𝒍 = 𝟓𝟓 ∗ 𝒅𝒅𝒆𝒆𝒆𝒆𝒆𝒆

The inlet channel has a width of 1 mm and after bifurcation our eight channels have the
width of 250 µm. All channels have a height of 60 µm with the exception of the waste reservoir
well which is .25 cm high. The final lengths and diameters of the channels are shown in Table 32. To see all of the calculations for the channel widths and length, please refer to Appendix 7.3.

Channel

Width
(µm)

Height
(µm)

Effective
Entry Length
Diameter (µm)
(µm)

Entry Length
(mm)

Final 8 Channels

250

60

138

691 =>

0.691

4 Channels After 2nd Split

397

60

174

871 =>

0.871

2 Channels After 1st Split

630

60

219

1097 =>

1.097

1000

60

276

1382 =>

1.382

1st Channel
Table 3-2 Channel Dimensions

3.2.4

Flow Characteristic
It has been shown that shear rate at the vessel wall is an essential factor in blood clot

formation both in vivo and in vitro. Flow velocity is positively correlated with shear rate given
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the dimensions of the micro-channel. In our chip design, the fluid flow rate is controlled such
that average shear rate at the channel wall is comparable to the in vivo shear rate, which is about
1000 s-1 in human arteries. With the channel dimension specification (w=250µm, h=60µm) and
the assumed physical properties of water for whole blood 2, the 3D velocity profile can be solved.
(See Appendix 7-11) The shear rate is defined by the following mathematical relation:
𝜸𝜸̇ =

𝒗𝒗

(3-8)

𝒉𝒉

where v(x, y) is a function of position of the cross-sectional plane and h is the distance from the
channel wall.
From the velocity profile, the fluid velocity required to achieve an average shear rate of
1000 s-1 is then computed to be 0.01 m/s or 1 cm/s.
Fluid flow is generally characterized by the Reynolds number (Re), which is a ratio of
inertia to viscosity. The dimensions of the microfluidic platform constrain the fluid flow to the
laminar regime, typically, with Reynolds number close to 1.

𝑹𝑹𝑹𝑹 =

𝒖𝒖𝒖𝒖
𝝂𝝂

=

𝟏𝟏𝟏𝟏−𝟐𝟐 𝒎𝒎
�×𝟗𝟗.𝟔𝟔𝟔𝟔×𝟏𝟏𝟏𝟏−𝟓𝟓 𝒎𝒎
𝒔𝒔
𝟔𝟔.𝟖𝟖𝟖𝟖×𝟏𝟏𝟏𝟏−𝟕𝟕 𝒎𝒎𝟐𝟐 /𝒔𝒔

�𝟏𝟏×

= 𝟏𝟏. 𝟒𝟒𝟒𝟒𝟒𝟒

(3-9)

where D is the characteristic length (in this case the hydraulic diameter of the channel crosssection) and 𝝂𝝂 is kinematic viscosity, assuming the physical properties of water.
The small Reynolds number implies that the flowing stream in the microchannel lacks
turbulence that is normally required for rapid mixing; this is one of the key limitations
confronting our chip design. To overcome the sluggish nature of this type of flow and accelerate

2

Blood plasma is 90% water. Therefore this is a reasonable approximation
- 61 -

mixing, a special structure has to be incorporated to the channel. Discussion on this issue will be
continued in the following sections.

3.2.5

Controlled Dissolution of the Embedded Anhydrous ADP and Clopidogrel
One of the major concerns of this design is the introduction of key reagents, namely ADP

and MRS 2395 (a P2Y 12 inhibitor), into the micro-channel. There are two options that achieve
this goal: 1) ADP and MRS 2395 in solution phase are injected into the microchannel by
mechanical penetration of the chip; or 2) They are deposited on the channel floor as dry reagents
readily dissolvable by the blood stream. However, it is almost apparent that the former requires
additional mechanical technology on the box design that not only necessitates micro-scale
precision to carry out fluid injection but also undoubtedly increases the cost of our project.
Furthermore, this mechanical addition adds extra burden on box-side cleaning. From the point of
care perspective, this looks appallingly unattractive.

The second option is a relatively simple

alternative that solves the aforementioned problems.
The incorporation of preserved reagents into a labon-chip device simplifies operation and increases
portability. Additionally, this design translates into
a classic well-defined mass transport problem that
helps the design team to further explore the
application of mass transport theories.

Figure 3-12: Fluorescence image of the anhydrous
reagent dissolution in a flow stream (41)

Incorporation of dry reagents onto the channel often entails the addition of stabilizing
preservatives.

For example, some proteins are preserved by drying in tetrahalose, which

stabilizes proteins by substitution of the water molecular of the hydrated proteins by the sugar
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molecules, thereby maintaining the native
form of the proteins.

(41)

Fortunately, ADP

and MRS 2395 are relatively stable as dry
reagents. No stabilizing reagents are required.
However, preserving ADP and MRS
2395 directly on the surface of the channel

Figure 3-13: Time dependence of the dissolved reagent
concentration in stream (41).

without some “anchoring” agents will certainly
result in washout of ADP and MRS 2395 at the first few seconds of operation. By drying ADP
and MRS 2395 in a heavy carbohydrate (usually Dextran), we essentially create a carbohydrate
matrix that encapsulates the dry reagents. This mesh sugar structure not only helps secure the
dry reagents in place but also establishes a relatively constant concentration gradient that in turn
gives us spatial and temporal control of the ADP & MRS 2395 concentration in the bulk fluid.
The reagents with carbohydrate in a well-mixed solution form are deposited onto the
floor of the channel by robotic pin tools. The solution is allowed to dry. Since the original
solution is well-mixed, the patterning of ADP & MRS 2395 can be assumed to be uniform. The
patch of dry reagents spans across the 250µm-wide channel and the length is yet to be
determined.
The release of ADP and MRS 2395 from the carbohydrate matrix and their subsequent
transport downstream may be controlled by parameters such as channel and patch dimensions,
patch shapes, fluid flow rate, and the chemical composition of the matrices. Under the prespecified flow rate and channel dimension, the only manipulative parameters are length of the
patch and the composition of the matrix, the latter of which will not be explored further here; it
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will be experimentally determined by trial and error. For the following discussion, the length of
the patch is computed by invoking the film theory model. Our problem is can be formulated as
laminar forced convection over a flat plate.
The problem can be translated into the following statement: Whole blood flows through a
patch with a constant ADP concentration C ADP,s . The dimension of the channel is specified; the
width, in the y direction, is 250 µm while the height, in the z direction, is 60 µm; the edge effects

CADP, ∞=0

V
A

Well
Mix

C

Bulk fluid

CADP

CADP,

B

Figure 3-14: Blood flow past a ADP concentration patch

in the y direction are assumed to be negligible. A theoretical boundary is drawn in Figure 3-14
to elucidate the focus of the problem. Now, it is clear that the release of ADP from point B must
equal to the amount of ADP leaving point C, which is the product of the volumetric flow rate V̇

and the well-mixed ADP concentrationCADP . The length of the ADP strip, x, must be designed
such that the flux of ADP at point B satisfies the material balance.

Under this modeling assumption, the Reynolds number, which is the ratio of inertial
forces to viscous forces, is defined mathematically as the following (42):
𝑹𝑹𝑹𝑹𝒙𝒙 =

𝝆𝝆𝒖𝒖∞ 𝒙𝒙
𝝁𝝁

=

𝒖𝒖∞ 𝒙𝒙
𝒗𝒗

(3-10)

where 𝑢𝑢∞ is the bulk fluid velocity; v is the kinematic viscosity (unit of m2/s); and x is the

position measured from the starting point of the patch. Therefore, Re x is a not constant value
across the length of the patch; it is a linear function of x.
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The Schmidt number, defined as the ratio of momentum diffusivity to mass diffusivity, is
used to characterize fluid flow that involves mass transfer. (42)
𝑺𝑺𝑺𝑺 =

𝝁𝝁

𝝆𝝆 𝑫𝑫𝑨𝑨𝑨𝑨

=

𝒗𝒗

𝑫𝑫𝑨𝑨𝑨𝑨

(3-11)

in which 𝜌𝜌 is the density of the fluid (kg/m3); D AB is diffusion coefficient (m2/s).
The Sherwood number, which is dimensionless ratio of convective to diffusive mass
transport, is defined as (42) , denoted by variables with a superscript bar:
�����
𝑺𝑺𝒉𝒉𝒙𝒙 = ����
𝒉𝒉𝒎𝒎

𝒙𝒙

(3-12)

𝑫𝑫𝑨𝑨𝑨𝑨

where ℎ𝑚𝑚 is the mass transfer coefficient. This definition is also valid in terms of average
quantities. From now on, the bar notation denotes average quantities.

The semi-empirical mass transfer correlation corresponding to forced convection over a
flat plate is taken from. (42)
𝟏𝟏/𝟐𝟐
�����
𝑺𝑺𝑺𝑺𝒙𝒙 = 𝟎𝟎. 𝟔𝟔𝟔𝟔𝟔𝟔 𝑹𝑹𝑹𝑹𝒙𝒙 𝑺𝑺𝑺𝑺𝟏𝟏/𝟑𝟑

(3-13)

Equation 3-12 is substituted into Equation 3-13 and ����
ℎ𝑚𝑚 is solved in terms of 𝑥𝑥:
����
𝒉𝒉𝒎𝒎 =

𝒖𝒖𝒖𝒖

𝝁𝝁

𝟎𝟎.𝟔𝟔𝟔𝟔𝟔𝟔� 𝒗𝒗 �𝝆𝝆𝑫𝑫
𝒙𝒙

𝑨𝑨𝑨𝑨

𝟏𝟏/𝟑𝟑

�

𝑫𝑫𝑨𝑨𝑨𝑨

(3-14)

The number of ADP molecules released from the plate is proportional to the
concentration gradient and the proportionality constant is ����
ℎ𝑚𝑚 𝐴𝐴𝐵𝐵 . (42)
𝒏𝒏𝑨𝑨𝑨𝑨𝑨𝑨,𝑩𝑩 = ����
𝒉𝒉𝒎𝒎 𝑨𝑨𝑩𝑩 �𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨,𝒔𝒔 − 𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨,∞ �

(3-15)

in which A B or the product of the width of the channel (W) and 𝑥𝑥 (𝑊𝑊𝑥𝑥) is the area of the

rectangular ADP patch; 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 is the concentration of ADP at the surface, which is manipulated
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experimentally; 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,∞ is the concentration of ADP initially in the bulk fluid (assumed to be 0

for now).

As discussed above, this number has be the same as the number of ADP molecules
leaving at point C by material balance:
𝒏𝒏𝑨𝑨𝑨𝑨𝑨𝑨,𝑪𝑪 = 𝑽𝑽̇𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨

(3-16)

𝒏𝒏𝑨𝑨𝑨𝑨𝑨𝑨,𝑩𝑩 = 𝒏𝒏𝑨𝑨𝑨𝑨𝑨𝑨,𝑪𝑪

(3-17)

����
𝒉𝒉𝒎𝒎 (𝒙𝒙)𝑨𝑨𝑩𝑩 �𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨,𝒔𝒔 − 𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨,∞ � = 𝑽𝑽̇𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨

(3-18)

Substituting the expression for ����
ℎ𝑚𝑚 and 𝐴𝐴𝐵𝐵 , the above equation is solved for x in terms of 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠
and we have:

𝒙𝒙 =

𝝁𝝁

𝒖𝒖�𝝆𝝆𝑫𝑫

𝟐𝟐.𝟐𝟐𝟐𝟐𝟐𝟐 𝒄𝒄̇ 𝟐𝟐 𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨 𝟐𝟐 𝒗𝒗

𝑨𝑨𝑨𝑨

𝟐𝟐/𝟑𝟑

�

𝑫𝑫𝑨𝑨𝑨𝑨 𝟐𝟐 𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨,𝒔𝒔 𝟐𝟐 𝑾𝑾𝟐𝟐

(3-19)

Four different values of 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 are desired in our design. In increasing order, they are 0.1,

1, 10, 100 times the IC50 (which is 2mM) of ADP, or 0.2mM, 2mM, 20mM and 200mM
respectively.

From the above relation, it is clear that the required length of the patch is

proportional to 𝐶𝐶𝐴𝐴𝐷𝐷𝐷𝐷 2 . If 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 (the surface concentration of ADP) is set constant, 𝑥𝑥 could range
from 100um for 0.2mM to 100m for 200mM. This range is not physically feasible in a chip with

a length of 6cm. On the other hand, 𝑥𝑥 can be set constant, 150um for the sake of consistent
dimensional design, and 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 is varied to achieve the 4 specified concentration of ADP. The
above relation is arranged to solve for 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 in terms of 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 .
𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨,𝒔𝒔 = �

𝟏𝟏.𝟓𝟓𝟓𝟓𝟓𝟓𝑽𝑽̇

𝟏𝟏
𝟑𝟑
𝒖𝒖𝒖𝒖
𝝁𝝁
� 𝒗𝒗 �𝝆𝝆𝑫𝑫 � 𝑫𝑫𝑨𝑨𝑨𝑨 𝑾𝑾
𝑨𝑨𝑨𝑨
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� 𝑪𝑪𝑨𝑨𝑨𝑨𝑷𝑷

(3-20)

Previously, we make the assumption that 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,∞ is approxomaely 0. To validate this claim, we

have to ensure that the boundary layer near the end of the patch does exceed the channel height
of 60 µm (42):
𝜹𝜹𝒄𝒄 ≈

𝟓𝟓𝟓𝟓

𝑺𝑺𝑺𝑺𝟏𝟏/𝟑𝟑 �𝑹𝑹𝑹𝑹𝒙𝒙

< 60 µ𝒎𝒎

(3-21)

Detailed calculation is performed in the Appendix 7.4. The results are tabulated:
C ADP,s (uM)

IC 50

C MRS2395 (uM) x (um)

Re x

Sc

Sh

δ C (um)

0

0x

0

149

2.18

705.5

8.7

57

24.8

0.1x

0.36

149

2.18

705.5

8.7

57

248

1x

3.6

149

2.18

705.5

8.7

57

2480

10x

36

149

2.18

705.5

8.7

57

Table 3-3: The required surface ADP concentration corresponding to in-stream ADP concentration (in red)

In conclusion, these values are only approximations. For further development of our
design, experiments are necessary to extract better estimates of these quantities. However, the
numbers and equations here serve as initial guesses for future trial and error experiments and
provide insight into the relationship between critical to quality variables.
3.2.5.1 Laminar Forced Convection over a Flat Plate
Peclet number, defined as the dimensionless ratio of convective motion to diffusive
motion, is another insightful indictor of fluid mixing behavior. On micro-scale, this diffusive
solute motion is slow relative to the convection of the solution along the channel, or Pe is large.
With our channel dimension specification, the Peclet number is computed as the following:
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𝑷𝑷𝑷𝑷 =

𝒖𝒖𝒖𝒖
𝑫𝑫

=

�𝟏𝟏×𝟏𝟏𝟏𝟏−𝟐𝟐 𝒎𝒎/𝒔𝒔�(𝟗𝟗.𝟔𝟔𝟔𝟔×𝟏𝟏𝟏𝟏−𝟓𝟓 𝒎𝒎)
𝟏𝟏𝟏𝟏−𝟏𝟏𝟏𝟏 𝒎𝒎𝟐𝟐 /𝒔𝒔

= 𝟗𝟗𝟗𝟗𝟗𝟗𝟗𝟗 ≫ 𝟏𝟏𝟏𝟏𝟏𝟏

(3-22)

where D is the molecular diffusivity, u is the velocity, l is the effective diameter of the
rectangular channel.
The small Re, implying the absence of turbulence, and the large Pe, meaning slow
diffusive solute motion, suggest the length required for mixing is unreasonably long. For such
unperturbed flows, the approximate distance along the channel required for mixing to occur is
suggested by (43)
𝒍𝒍𝟐𝟐

𝜟𝜟𝒚𝒚𝒎𝒎 ≈ 𝒖𝒖 × � � = 𝑷𝑷𝑷𝑷 × 𝒍𝒍 = 𝟗𝟗𝟗𝟗𝟗𝟗𝟗𝟗 × 𝟗𝟗. 𝟔𝟔𝟔𝟔 × 𝟏𝟏𝟏𝟏−𝟓𝟓 𝒎𝒎 = 𝟎𝟎. 𝟗𝟗𝟗𝟗𝟗𝟗 (3-23)
𝑫𝑫

This length is reasonably long given the dimensional limitation of the chip. Adding to its
disadvantage, the unperturbed flow requires mixing length that grows linearly with velocity/Pe,
rendering the re-usability of the pre-designed micro-channel at different flow conditions
impossible.
To circumvent this problem, we need to introduce a structure that mimics the effect of
turbulence. There are 3 options that have been
intensely and thoroughly researched: squarewave,
serpentine and herringbone. Due to the simplicity
of its fabrication, the herringbone configuration is

Figure 3-15: Cross-sectional view of fluid flow
pattern in the micro-channel (43)

generally deemed to be one of the most costeffective designs for mixing in micro-channels. With PDMS as the raw material for chip
fabrication, the mold for the herringbone grooves were made possible by a two-level photolithography. These grooves which were recessed into the floor of the flowing channel induce
transverse components of flow that stretch and fold volumes of fluid. These stirring flow
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patterns reduce the average distance over which diffusion must act in the transverse direction to
homogenize unmixed volumes. (43) As a result, mixing length is substantially reduced. Before
we continue, it is deemed necessary to briefly review the concept of mixing in micro-channels.
The quality of mixing can be characterized by coefficient of variation (CV). Mixing analysis
generally assumes there are two steams flowing side by side; one contains the solutes dissolved
uniformly in solvent and the other is pure solvent.
concentration variation between the two streams.

The CV quantifies the degree of

Experimentally, the degree of mixing is

evaluated after confocal microscopy is performed on the mixing streams. The CV can be
extrapolated from image analytical techniques. Since the initial design of the herringbone mixer,
analytical modeling of it becomes an intense area of research. The most complex methods
involve computational fluid dynamics (CFD) modeling, which considers the redistribution of
streamlines and reduction of striation thickness.

Though these methods generally give a

comprehensive picture of the mixer, the mathematical modeling can be prohibitively challenging,
if not impossible.
A simple analytical model accompanied
the herringbone mixer adapted from

(44)

with

minimum modification due to similarities in
design specification is presented here to analyze
the degree of mixing as a function of Pe and
length by assuming uniform residence time
distribution of SHM. At molecular level, solute in

Figure 3-16: Exact solution of l01 vs. Pe in semi-log
plot

each fluid element must diffuse to the other fluid for mixing to occur. Diffusion from a point
source follows a normal distribution, and the mean magnitude is denoted by 𝐿𝐿𝑑𝑑 = √2𝐷𝐷𝐷𝐷, where
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D is diffusivity and t is the duration of the diffusion . The probability that the solute has diffused
the distance L d with the boundary limit of L i is computed by (44) as:
𝟏𝟏

𝟐𝟐√𝟐𝟐𝑳𝑳𝒊𝒊

𝑷𝑷 (𝑳𝑳𝒅𝒅 < 𝑳𝑳𝒊𝒊 ) = 𝒆𝒆𝒆𝒆𝒆𝒆 �
𝟐𝟐

𝑳𝑳𝒅𝒅

�≈

𝟏𝟏.𝟔𝟔𝟔𝟔𝑳𝑳𝒊𝒊
𝑳𝑳𝒅𝒅

(3-24)

The expression for L d is substituted with the definition of Pe. The following expression form
(44)

is obtained:

𝑷𝑷 (𝑳𝑳𝒅𝒅 < 𝑳𝑳𝒊𝒊 ) = 𝟏𝟏. 𝟔𝟔𝟔𝟔�

𝑷𝑷𝑷𝑷

𝒘𝒘𝒘𝒘𝒘𝒘

𝑳𝑳𝒊𝒊

(3-25)

The empirical relation between l and L i is computed by MATLAB with COMSOL data by (44):
𝑳𝑳𝒊𝒊 = 𝟏𝟏𝟏𝟏. 𝟕𝟕 𝐞𝐞𝐞𝐞𝐞𝐞(−𝟎𝟎. 𝟓𝟓𝟓𝟓 𝒍𝒍)

𝑹𝑹𝟐𝟐 = 𝟎𝟎. 𝟗𝟗𝟗𝟗𝟗𝟗

(3-26)

This is substituted into the previous equation and solved for 𝑙𝑙0.1 with an arbitrary cutoff

probability of 0.1. The exact solution is generated by Maple 11 and graphed (Figure 3-16). This
is approximation of the solution
𝒍𝒍𝟎𝟎.𝟏𝟏 ≈ 𝟏𝟏. 𝟕𝟕𝟕𝟕 𝐥𝐥𝐥𝐥𝐥𝐥(𝑷𝑷𝑷𝑷) − 𝟐𝟐. 𝟏𝟏𝟔𝟔

(3-27)

The exact value of 𝑙𝑙0.1 is 4.58 cycles corresponding to Pe of 9680 from Figure 3-16. This value

computed by using the analytical model agrees to a reasonable extent with the experimental
value (Figure 3-17). It is important to note that 𝑙𝑙 is expressed in terms of cycle numbers;

therefore the length per cycle multiplies the cycle number, 𝑙𝑙, to give the actual length of the
mixer.

𝑳𝑳 = 𝒍𝒍𝟎𝟎.𝟏𝟏 × 𝒅𝒅 = 𝟒𝟒. 𝟓𝟓𝟓𝟓𝟓𝟓

(3-28)

where d is the length of one cycle, which is computed as the following:
𝒅𝒅 = 𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅 𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈 𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎 𝒇𝒇𝒇𝒇𝒇𝒇𝒇𝒇 𝒕𝒕𝒕𝒕𝒕𝒕 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 × 𝒕𝒕𝒕𝒕𝒕𝒕 𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏 𝒐𝒐𝒐𝒐 𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈𝒈 𝒑𝒑𝒑𝒑𝒑𝒑 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 =
𝟏𝟏𝟏𝟏𝟏𝟏𝟏𝟏𝟏𝟏 × 𝟏𝟏𝟏𝟏 = 𝟎𝟎. 𝟐𝟐𝟑𝟑𝟑𝟑 𝒄𝒄𝒄𝒄
(3-29)
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The length can then be computed to be 1.06 cm. Most importantly, note that the mixing
length, 𝑙𝑙 is proportional to log(Pe), implying
more “resistance” to perturbations in flow rate.
This elegant feature introduces stability and reusability in our chip design, as this configuration
can be employed to give only slight changes in
mixing length under different flow conditions. In
addition, the mixing length is reduced from 93 cm

Figure 3-17: Comparison of analytical model and
experimental data (44)

to about 1cm, a scale that is compatible with our
chip dimension. Although 1 cm is manageable in terms of size, additional manipulative design is
required to efficiently maximum the space utilization.
Due to the chip dimensional constraint (with a width of 4 cm and a length of 6 cm), the
herringbone supplemented micro-channel mixer is still relatively long and should not be
linearized; it must be in a compacted form to accommodate the rest of the components of the
chip. To achieve this purpose, the squarewave configuration is employed.
3.3

MCCRA Device
The basic concept of the device is a box type structure into which the disposable chip can

be inserted. Once inserted, a vacuum will puncture through the PDMS into the waste reservoir in

Figure 3-18 Flow chart showing the basic mechanisms of the device’s operation.
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order to provide the negative pressure required to make the blood flow through the chip. Also
within the device will be a row of eight white light emitting diodes (LEDs) situated above where
the collagen portion of the chip will sit. Below the lights there will be a transmission detector.
Readings from the detector will be transmitted to an electronic device that will be connected to a
computer. The device will convert the readings into the necessary format to be read by the
computer program.

(This analysis and graphing software will be developed by a hired

programmer). The program will display a comparison of the transmission data to the IC50 curve
for MRS 2395. Accompanying the program will be a manual of standard ranges for healthy
individuals and the clinical implications of variations from these ranges, based on data acquired
through testing and clinical trials. From this the doctor can interpret the results and determine
the proper clopidogrel dosing amount. The vacuum will run for a total of 5 minutes, and
readings will be taken in 5 second intervals. Once the data has been collected, the chip will be
ejected from the device (See Figure 3-18).
Due to limited knowledge of electronics and electrical engineering, a consultant advised
the outsourcing of the manufacturing of the device. The consultant suggested a “black box” style
device, into which the MCCRA’s specifications can be added and an already existing electronic
“reader” on the box can be programmed to this product’s specific needs.

3.3.1

Instruction for Device Usage
Press “on” button to turn on device. Remove MCCRA chip from refrigerator, and then

remove from the sterile packaging. Put patient’s blood sample onto designated location on the
MCCRA chip. Insert chip into device, and press “start” button. When device has finished
operation, the red “complete” light will turn on. Remove chip from device and dispose in
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hazardous/biological waste container. Use computer readout and compare to MRS 2395 IC50
curves to determine dosing amount.
3.4

3.4.1

Data Analysis
Prototype Findings
The photomask was designed in LayoutEditor 3. In order to probe the feasibility of the

design of our chip, a high-resolution (10,000
dpi) transparency of the chip design was
printed 4 KMPR 1050 positive photoresist 5 was
spun on a silicon wafer 6 on a CEE 100 7 spinner
for 30 seconds at 3000 rpm to achieve a
thickness of 62μm 8. Following a soft bake at
100C for 15 minutes, the wafer was aligned
with the aforementioned mask using a Karl Suss
MA4 9 mask aligner, then exposed to 365nm

Figure 3-19 PDMS block consisting of our chip design.
Presence of defined and correctly patterned features, such
as channels, mixing regions and reservoirs, has instilled
confidence in our product design. Note: the upper left
section of the chip shows the vacuum being punctured into
the waste well.

light at a constant intensity of 5mW/cm2 for 195 seconds to manufacturer’s recommendations of
975mJ/cm2 exposure energy.

Following a post exposure bake at 100C for 3 minutes, the

unreacted photoresist was removed with AZ 300 MIF 10 developer for 10 minutes under constant
agitation.

3

After fabrication, the master was silaized for three hours with 1,1,2,2-

Jürgen Thies
CAD/Art Services, Bandon, OR
5
Microchem, Newton, MA
6
100mm diameter, <100>, Virginia Semiconductor, Fredericksburg, VA
7
Brewer Science Inc., Rolla MA
8
measured post-fabrication using a Tencor Alpha Step (KLA-Tencor Corp, San Jose, CA)
9
Karl suss, Garching, Germany
10
Clariant Corp., Somerville, NJ
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tetrahydrooctyle-1-trichlorosilane 11 to facilitate PDMS removal.

The master was used to

fabricate the mold in a process similar to that of the manufacturing mold design. 80mL of PDMS
pre-polymer was mixed at a 1:10 ratio with curing agent 12 and degassed, then poured onto the
master. This device was placed in an 80°C oven for two hours, and then removed, cut from the
mold, and ports punched. (45)
For proof of concept purposes, a number of
analogous yet simplified chip designs were included on
the master in addition to the intended microfluidic
device. The simplified analogue consisted of only one
of the eight channels. The same vacuum setup that
would have been used for the more complex
microfluidic chip was used for the single channel. The

Figure 3-21 A Harvard PHD 2000 Syringe Pump
was used as the driving force for flow in our
prototype.
The syringe pump was set at a speed that
mimicked the sheer rate of blood found in vivo.

prototype

testing

was

therefore

intended to prove three things: that the
chip design was capable of being
manufactured, that MRS 2395 inhibits
aggregation of platelets, and that
platelet aggregation would occur on
the collagen. Positive evidence for
Figure 3-20 Microscope setup used to record platelet aggregation by
measuring changes in light transmittance.

11
12

United Chemical Technologies, Bristol, PA
Sylgard 184, Dow Corning, Midland, MI
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these factors would indicate that hard

to measure system characteristics, such as specific concentration gradients, were correctly
calculated.
With the microfluidic chip fabricated, the design was now ready to be tested. However,
lab equipment needed to be used as substitutes for functions the box would normally perform. A
lab-scale syringe pump 13 was substituted for the vacuum pump to apply a constant flow rate
across the channel. Upon obtaining blood from a willing volunteer, it was allowed to mix off
chip with ADP in a 1.5 mL tube. From this mixture, approximately 200 µL were applied to one
end of the channel while the syringe pump was attached to the other end of the channel. Similar
to the way our box will assay the chip, the prototype was mounted on an inverted microscope 14
and light transmittance through the collagen patch was measured as a function of time. Images
were collected every five seconds over a five minute period. To get an accurate numerical image
of the light transmittance, a 10X objective was used. After a few trials, the experiment clearly
showed the aggregation of platelets on the surface of the collagen. To bridge the gap between
prototype and desired product even further, the blood and ADP mixture was incubated with
varying concentrations of MRS 2395 and platelet aggregation was further tested.

3.4.2

Image J
Although the MCCRA will utilize a sophisticated computer algorithm capable of

advanced interpretation and manipulation of recorded data and error detection ability, the
prototype findings were susceptible to analysis with the ImageJ Image Processing program.

13
14

PHD 2000, Harvard Apparatus, Holliston, MA
Olympus IX81, Olympus America, Center Valley, PA
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As the blood was run through the chip, a CCD camera 15 captured a black and white
image of the channel every 5 seconds over the experimental time period of five minutes. These
pictures were then uploaded to ImageJ, where a region of interest was selected around the
collagen patch of the channel and another area was drawn around an upstream part of the channel
devoid of collagen. The average grayness of the boxes (dark boxes equals less surface height,
lighter surface equals higher surface height) were determined from intensity profiles from those
regions, and the difference between the average pixel intensity of the collagen-free area and
collagen area was calculated. This value was divided by the average intensity of the collagenfree region and relative intensity value was determined. These values were plotted versus time
and the trends were observed.
3.4.3

Results
As found in Figure 3-22, blood plus ADP initially mixed with inhibitor at 5, 10 and 50 µM

was flowed over a collagen patch. The y-axis plots the relative grayness of the patch, which is a
measure of the topology of the surface. The graphs all individually show a transient regime
where platelet aggregation begins and increases steadily. A steady state value for the signal is
then attained, normally when the experimental time equaled about 250 seconds. Compared
against each other, the experimental trials lead to the conclusion that a more concentrated MRS
2395 solution leads to less platelet aggregation. In addition, the experiments using 10 µM and 50
µM inhibitor show graphs that lead to a similar steady state platelet aggregation. These graphs
imply that a boundary is reached at above 10 µM MRS 2395, and thus any additional inhibitor is
without effect.

15

ORCA-ER, Hamamatsu, Bridgewater, NJ
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Figure 3-22 The platelet aggregation is recorded as a function of time.
Aggregation was determined from a measure of pixel grayness, which is an indication of the surface topology. A darker
surface (lower pixel grayness value) translated to less surface structures, while a lighter surface (higher pixel grayness
value) meant higher surface structures.

3.4.4

Dose Response Curve
The steady state values

from the experiments were used to
construct a very elementary doseresponse curve. Shown in Figure
3-23, the graph demonstrates the
effects of the increasing MRS
2395 concentration on platelet
aggregation. Does-response curves
are normally characterized by a
sigmoidal shape, where the steepest

Figure 3-23 The results of increasing inhibitor concentration on platelet
aggregation. The points shown represent the upper portion of the sigmoidal
dose-response curve.

(slope) portion of the curve is located in the middle of the graph, while the lower and higher
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points show little change. Expecting the results in Figure 3-23 to be similar, the data points
collected must occur after the inflection point of the sigmoidal curve. Therefore, the
concentration of inhibitor used in this study must have been above the concentration that gives
half inhibition of receptors and gives us an idea of the IC 50 for MRS 2395 against the P2Y 12
receptor. One study of rat platelet aggregation found an IC 50 of 3.6 µM, corresponding well with
the data found here. (46)
The curve serves to successfully prove the contention that MRS 2395 functions to inhibit
platelet aggregation. Since it behaves as intended, the inhibitor should be successful in allowing
the MCCRA to ascertain the amount of P2Y 12 receptors that have not been inhibited clopidogrel.
Thus, all of the proof of concept points have been accurately answered and the prototype
validated.
3.5

3.5.1

Financial Analysis
Market Share and Sales Project
It has been shown that pre-treatment with clopidogrel before primary percutaneous

coronary intervention (PCI) lowers the risk of future complications based angiographic outcomes,
thus significantly reducing the risk of cardiovascular death.

(47) (48)

The number of PCI cases

performed annually is 1.1 million in the US as of 2008. Since the benefit from pre-treatment
with clopidogrel before PCI has been known for at least 2 years, 90% of the patients requiring
PCI, or about 1million, are currently pre-treated with clopidogrel. Presumably, all clopidogrel
prescription requires dosage measurements.
For our project development, one year (Year 2010) is allocated for product design and
development from the prototype. The Food and Drug Administration approval and regulation
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processes are generally expected for startup biotech devices that are used in health care settings.
This process is anticipated to take 2 years (Year 2011 and 2012), a relatively short period due to
the non-invasive nature of our device. The expected date for launching our product is the
beginning of 2013 and it is expected to initially capture 10% of the market share (1 million) or
100,000 patients.

It is anticipated this number will grow thereafter due to the increasing

awareness of the benefits from clopidogrel and the competitive advantage of our product. The
market share is expected to follow a step increase from 10% initially to 30% for the second year
of operation, and finally 50% until the end of operation.
Previously it has been shown that the market for clopidogrel resistance detection is
fiercely competitive (See Competitive Analysis 2.8).

Several devices employing different

clotting quantification techniques (for example, florescence transmittance aggregometry,
turbidity measurement, electro-conductivity measurement etc) are competing to be the gold
standard. Their prices per test range from $50 to $100, while their run times plus incubation
vary from 13 minutes to hours. If the time is considered an opportunity cost, the most costeffective price and run-time combination charges 650 min*dollar/test (VerifyNow). As the
world is looking for a cost-effective, high-throughput device that efficiently measures
clopidogrel resistance with sophisticated error checking mechanisms, we introduce our POC
high-throughput screening device that utilizes high performance microfluidic technology that
enables us to charge only $100 per 4 tests per 10 minutes (250 min*dollar/test). From the time
and cost perspectives, our product is expected to be at least 2.5 times more efficient than any of
its existing competitors.
In the subsequent revenue estimation, monetary figures are expressed in real terms (in
today’s money value). Inflation is not incorporated into our financial models, because it is
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impracticable to accurately predict inflation rate based on historical data. Furthermore, it is
important to note that cash flow discounting (CFD) using quantities in real terms with the real
discount rate is theoretically equivalent to CFD using quantities in nominal terms with nominal
discount rate. It is clear that estimating inflation rate and adjusting discounted revenues and
costs accordingly is superfluous. The real discount rate is related to the nominal discount rate
and inflation rate by the Fisher equation:
𝟏𝟏+𝑵𝑵𝑵𝑵𝑵𝑵𝑵𝑵𝑵𝑵𝑵𝑵𝑵𝑵 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫 𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹
𝟏𝟏+𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰𝑰 𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹

− 𝟏𝟏 = 𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫 𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹

(3-30)

Cash Flow Discount (CFD) will be discussed in more detail in later sections.

Our plant

operation is anticipated to last 7 years, after which the patent expires or our product loses its
competitive edge to new technologies.

The annual revenue from MCCRA chip sales is

summarized in the following table:
Year

2013

2014

2015

2016-2019

% Market

10%

30%

50%

50%

100,000

300,000

500,000

500,000

$100

$100

$100

$100

$10,000,000

$30,000,000

$50,000,000

$50,000,000

Test/Yr
Chip Price
Revenue

Table 3-4 Revenue Table

3.5.2

Expenses
Our design group has attempted to get in contact with sales representatives from various

chemical suppliers. A rough estimate of the costs of the raw materials for the chips, equipments,
and general expenses were obtained. Due diligence in the form of thorough research was
performed to verify the quotes from these sales representatives. It was recognized that these
prices might represent an overestimation because quantities would be purchased in bulk,
resulting in a discount. Moreover, if the project was carried beyond the design stage, better deals
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with the suppliers might be negotiated. For the purpose of initial design, the prices found were
satisfactory. For subsequent cost analyses, the expense worksheet is dissected into the following
3 categories: 1) total initial capital investment 2) variable costs, 3) fixed costs. Each of these will
be discussed in detail in the following subsections.
3.5.2.1 Total Capital Investment
Table 3-5 provides a summary of the items that are part of property, plant and equipment
(PPE). The focus of our project is product design, so all will be pre-fabricated upon purchase
from suppliers. However, before the purchase of some of these pieces of equipment (such as the
oven, stirred tank, and cold room storage), equipment sizing has been performed (Appendix 7.7).
With these sizing estimations, equipment with relevant capacities is chosen to avoid needless
costs. For example, the necessary storage space to accommodate a monthly inventory of 42,000
chips is computed to be 70 cubic feet, while the refrigerator unit has a volume capacity of 78
cubic feet. The sizing-aided selections of other equipments are carried out in a similar fashion.
As mentioned previously, the quotes for all equipments are obtained from sales
representative and supplier websites. For example, Silverson Laboratory Scale Batch Mixer
costs about $1,500, taken from the Silverson website. Bare modules factor for this item is 1.0
because there is no extra installation fee associated with it; the mixer is pre-fabricated and preconfigured upon purchase. The bare module cost (𝐶𝐶𝐵𝐵𝐵𝐵 ) is the product of the bare module factor

(𝐹𝐹𝐵𝐵𝐵𝐵 ) and the purchase cost (𝐶𝐶𝑃𝑃 ):

𝑪𝑪𝑩𝑩𝑩𝑩 = 𝑭𝑭𝑩𝑩𝑩𝑩 × 𝑪𝑪𝑷𝑷

(3-31)

The bare module costs for all other process equipments, the storage, security system, and lab
computers & software are computed in a similar fashion.
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Table 3-5 Equipment and Related Costs

It should be noted that bare module factors associated with different equipments are not
the same. For example, the bare module factor of 1.5 for Biomek FX Robotic Arm reflects that
the cost of installation is 50% of the purchase cost, while a bare module factor of 2 for
Wisconsin Industrial Oven suggests that another 100% of the purchase cost is used in setting
ventilation system associated with its installation. All of the aforementioned items are purchased
during the design stage in 2010. The rest of the section is devoted to addressing the box and
FDA approval expenses.
The box manufacture will be out-sourced to an electronic supplier. A list of functional
specifications will be provided to the box manufacturer to customize the box.

Table 3-6

summarizes the components in the box as well the cost of assembly (which is estimated to be 50%
of the aggregate purchase costs of individual components). It is essential to note that the box
will not be processed by our chip manufacturing plant and one box is directly distributed to one
hospital that hold contract with our service. The box selling price is the same as the selling price
required by the electronic supplier; in another words, we make no profit out of the sales of the
box. This should be deemed reasonable because we as the chip manufacturing side do not add
extra value to the box. Therefore, the box sales will not appear in our financial analysis, while
box maintenance and technical support will be considered. In Table 3-5, there is a “Box free
trial” entry under “Other Equipments”. One major reason is that most of the hospitals (we are
targeting about 4000 large hospitals in the US) already purchased our competitors’ boxes; these
expenses represent sunk costs to them, costs that they incurred in the past. For this reason, they
might not be willing to dispose these boxes and replace them with ours. Hence, we will purchase
50 boxes and offer them as free trial products to 50 selected hospitals in 2013 (1st year of
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operation). This business strategy will not only ensure us market share, but also support our
marketing effort.
The cost of FDA approval excluding overhead expenditure is assumed to be 10% of the
annual sales at full capacity, or $5 MM, evenly distributed over the 2 year period (2011 and
2012). Overhead is defined as all costs but direct labor and materials on the income statement.
This is treated as “other equipment” in the profitability worksheet. It is important to recognize
FDA approval is not a one-time cost. Congress enacted the Medical Device Amendments of
1976 to further FDA regulation on the safety and effectiveness of medical devices

(49)

. The

medical device regulation generally can be divided into 2 stages: 1) pre-market evaluation and
approval process and 2) post-market evaluation. This implies overhead expenditures will be
allocated to deal with federal regulation on an annual basis. Therefore, for economic analysis at
the design stage, it is convenient and reasonable to treat the $5 MM spent on FDA approval as
depreciable capital investment, and overhead is computed as a percentage of this amount
annually. This will be discussed in detail in the section on (Fixed Costs 3.5.2.3). Some of the
plant equipments and process facilities need modifications of the factory for installation. For
example, ventilation system might have to be set up before installing the oven. We account for
this type of expenses within Cost of Site Preparation in Table 3-5, which is taken as 5% of bare
module costs.

(50)

To maintain a well-managed, orderly factory, service facilities are

indispensable and take about 5% of bare module costs. (50) The sum of bare module costs, cost of
site preparation and service facilities is denoted as the Direct Permanent Investment (DPI). The
cost of contingencies and contractor fees is about 18% of DPI. The accumulated sum of DPI and
cost of contingencies and contractor fees is known as Total Depreciable Capital (TDC). The cost
of land is not included in the section because the manufacturing facility will be rented. The
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annual rent payment is treated as fixed cost in annual basis in the section on Fixed Costs. Finally,
there are costs incurred for the plant start-up, which is usually 2% of TDC (50). Working capital,
which includes accounts receivable, cash reserves, accounts payable and inventory, is about 12%
of annual sales at full capacity, or 1 month of sales revenue. The sum of the aforementioned
items is lumped together as the Total Capital Investment (TCI). It should be noted that TCI is a
one-time cost, in contrast with fixed costs and variable costs, which we incur on an annual basis.

Table 3-6 The box price is estimated by taking the sum of the costs of individual components and adding the installation cost
and required profit from the out sourced company.
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3.5.2.2 Variable Cost
The variable cost is defined as the cost per unit of merchandise produced. It is
partitioned into 3 major categories: raw materials, utilities, general expenses. As mentioned
previously, the quotes for the raw materials expressed in terms of either per volume basis or
per mass basis are obtained from supplier sales representatives. Material balance is carried
out to compute the amount of each reagent needed to produce 1 chip (refer to section on
chip manufacture). With this, the cost of each reagent per chip can be calculated (Table 3-7).
In the United States, energy consumption is reported ranging from $1.50 to $2.50 per
square foot in a typical building (51). With area occupancy of 2500 square feet, our plant
utility cost can reach up to $6250.
This is considered the most basic cost in our manufacturing plant. However, the
most utility-consuming equipments that are used in chip production include a group
comprised of the oven, robotic pin tools and the packaging machine. The power of all these
equipment can be found in their product descriptions and multiplied by operation time and
cost per utility unit to give the costs of utilities expended by them. The overall cost of utility
is the sum of the cost for a typical building and the cost from utility heavy equipments.
Nonetheless, for simplicity, we just multiple a factor of 1.2 to account for extra cost of
utilities by these equipments here:
𝑼𝑼𝑼𝑼𝑼𝑼𝑼𝑼𝑼𝑼𝑼𝑼𝑼𝑼 𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪 = 𝟏𝟏. 𝟐𝟐 × 𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻 𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪 𝒇𝒇𝒇𝒇𝒇𝒇 𝒂𝒂 𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃𝒃 = 𝟏𝟏. 𝟐𝟐 × 𝟔𝟔𝟔𝟔𝟔𝟔𝟔𝟔 = $𝟕𝟕𝟕𝟕𝟕𝟕𝟕𝟕 𝒐𝒐𝒐𝒐 $𝟎𝟎. 𝟎𝟎𝟎𝟎𝟎𝟎/𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪 (3-32)

The cost items listed above are the most obvious or direct expenses incurred in

producing chips. However, the less obvious or indirect costs are lumped together as General
Expenses, which include transportation, direct research, allocated research, administrative
expense and management incentives. All these expense items are computed as percentages

of annual sales: 3% for product transfer, 4.8% for direct research, 0.5% for allocated
research, 2% for administrative expense and 1.25% for management incentive compensation
(or bonus). These are normally considered variable costs instead of fixed costs because
annual sales actually vary for the first 3 years of operation.
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Table 3-7 Costs of Each Reagent per Chip

3.5.2.3 Fixed Cost
The fixed cost includes the costs from annual operation, maintenance, operating
overhead, property taxes and insurance, and space rental. In the rest of the section, a
comprehensive review of each cost is given.
Operations include 1) direct wages and benefits (DWB), 2) direct salaries and
benefits (DSB) and 3) operating supplies and services (OSS). To compute DWB, it is
deemed necessary to elucidate a few operating conditions. Firstly, the operating hour is
allotted 10 hr per day such that the manufacturing process can achieve the production of
4000 chips daily. Secondly, the number of operation days per year is assumed to be 250, or
70% of 360 days/1 year. The other 30% of the time is spent on maintenance and inspection;
this is a typical assumption for a biomedical manufacturing plant.

(50)

Thirdly, the number

of operators per shift is estimated by considering the amount labor required for each process
in the production chain (Table 3-8). Lastly, the hourly rate of $42.5/hr is adopted from a
similar project titled “High throughput screening of kinase inhibitors” in
and benefits are the following function of the aforementioned variables:

Type of Process

Number of Operators per
Process Section

Mixing of PDMS and curing reagents

1

Pouring PDMS onto molds

2

Curing in oven

1

Depositing ADP, MRS, and collagen

5

Sealing chip with glass slide

3

Packaging

3

Total

15

Table 3-8 Estimation of the number of operators.
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(50)

direct wages

𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫 𝑾𝑾𝑾𝑾𝑾𝑾𝑾𝑾𝑾𝑾&𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩𝑩 = �𝟏𝟏𝟏𝟏

𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶𝑶
𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔

� (𝟏𝟏 𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔) �𝟐𝟐𝟐𝟐𝟐𝟐𝟐𝟐

𝒉𝒉𝒉𝒉
𝒚𝒚𝒚𝒚

$𝟒𝟒𝟒𝟒.𝟓𝟓

− 𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐� (

𝒉𝒉𝒉𝒉

)

(3-33)

To continue our calculation of direct salaries and benefits (DSB), it is necessary to clarify
the distinction between DSB and DWB. Direct wages and benefits are paid to operators
who are directly involved in production while direct salaries and benefits are compensated
to supervisory and engineering personnel who oversees the operation. Direct salaries and
benefits is usually 15% of DWB and added to DWB to give the total labor cost of plant
operation (50). It is clear labor itself will not accomplish the entire operation. Operating
supplies and services are generally essential and usually taken as 6% of DWB (50); these are
the tools beside the plant equipments that the operators use to carry out their tasks.
Similarly, maintenance cost include 1) Maintenance Wages and Benefits (MWB), 2)
Maintenance Salaries and Benefits (MSB), 3) Materials and Services (analogous to
operating supplies and services), and 4) Maintenance Overhead. The distinction between
MWB and MSB is analogous to the difference between DWB and DSB; generally salaries
refer to supervisory personnel compensation in this report. Since maintenance is done on
the plant equipment (Total Depreciable Capital), MWB should be proportional to TDC; in
fact, MWB is taken as 4.5% of TDC here. It is common practice to take 25% of MWB as
Maintenance Salaries and Benefits. Materials and services take into account for spare parts
and external technical support for repairs. This is usually 100% of the Maintenance Wages
and Benefits because machine parts and repair services are quite hefty. Accounting fees,
legal fees, utilities etc. that we incur during maintenance are classified as maintenance
overhead, which is 5% of MWB, typical for a biomedical manufacturing plant. (50)
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Figure 3-24 Chip Cost Composition

In addition, there are overhead expenses that are associated with the operation as
well. This can be broken down to 1) general plant overhead, 2) mechanical department
services, 3) employee relations department, and 4) business services. These expense items
are rather self-explanatory or previously addressed, and 7.1%, 2.4%, 5.9%, and 7.4% of the
sum of DWB and MWB, respectively.
Rental fee for factory and office space is computed based on cost per square feet and
estimated size of our plant:
𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨 𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹𝑹 𝑭𝑭𝑭𝑭𝑭𝑭 =

𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪
𝒇𝒇𝒇𝒇𝟐𝟐

× 𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐 & 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑠𝑠𝑠𝑠𝑎𝑎𝑎𝑎𝑎𝑎 3-34)

The fixed cost components are tabulated in Table 3-9.
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Table 3-9: A summary of fixed cost

3.5.3

Valuation/Discounted Cash Flow
The fundamental principle of the time valuation of money tells us that a dollar today

is not the same as a dollar a year from today, simply because if we invest a dollar today in
the market, we will get back a dollar plus interest. Similarly, a dollar a year from today is
worth actually less than a dollar today. It is clear that the money values at different times
are somehow related. This seemingly intricate relationship is unexpectedly simple; all cash
flows at different times can be jointly expressed, that is, in the form of the discount interest
rate (52):
𝑵𝑵𝑵𝑵𝑵𝑵 = 𝑪𝑪𝟎𝟎 +

𝑪𝑪𝟏𝟏

(𝟏𝟏+𝒓𝒓)

+

𝑪𝑪𝟐𝟐

(𝟏𝟏+𝒓𝒓)𝟐𝟐

+ ⋯+

𝑪𝑪𝒕𝒕

(𝟏𝟏+𝒓𝒓)𝒕𝒕

(3-35)

where C subscript represents the cash flow at date 0 (or today), date 1, date 2 and so on.
The net present value (NPV) is the sum of discounted cash flows; in another words, paying
one all these cash amounts (C 0 , C 1 ...C t ) at different times is equivalent to paying him/her a
lumped sum of NPV today. Therefore, once we know the discount rate, we can express our
project sales and costs in terms of money today.
Simple as it seems, estimation of the discount rate is one of the major challenges in
financial analysis. Often, the discount rate is misinterpreted as simply the interest rate in the
bank, while in reality it is the expected return on the asset. For this reason, we will expound
on how we obtain the discount rate through the capital asset pricing model (CAPM):
� = 𝑹𝑹𝑭𝑭 + 𝜷𝜷 × (𝑹𝑹
� 𝑴𝑴 − 𝑹𝑹𝑭𝑭 )
𝑹𝑹

(3-36)

𝑅𝑅� is the expected return on our project (taken as the discount rate). 𝑅𝑅𝐹𝐹 represents the risk

free expected rate of return or the current return on 10-year treasury bills, which is 2.7%. (53)
𝑅𝑅�𝑀𝑀 is the expected return on the market and estimated to be 10.83% based on the Dow Jones
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Industry Average from 1975 to 2006. (54) The difference between 𝑅𝑅�𝑀𝑀 and 𝑅𝑅𝐹𝐹 , 8.13%, known
as the market risk premium, is always positive because average return on the market is

higher than riskless interest rates historically. 𝛽𝛽 is a measure of risk or volatility on return
associated with our project. The exact definition can be clarified by this equation:
𝜷𝜷 =

𝑪𝑪𝑪𝑪𝑪𝑪(𝑹𝑹𝒊𝒊 ,𝑹𝑹𝑴𝑴 )
𝝈𝝈𝟐𝟐 (𝑹𝑹𝑴𝑴 )

3-37)

The numerator is the covariance between

return on a similar project and average
return

on

the

market,

while

the

denominator is the variance of the
average return on the market.

We

selected few biotech startup companies
Table 3-10: beta estimation from similar stocks

from the market and take the average of their
beta values to give a crude estimate of the beta value for our project. (55) Given all the
required inputs into Table 3-11, the discount rate is then calculated to be about 15%. Now,
we have all the information we need to construct the cash flow table; in summary, the
required parameters are initial capital investment, variable cost/year, fixed cost/year and the
discount rate. The net present value (NPV) and investor rate of return (IRR) are also
included in Table 3-11.
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Table 3-11: Cash Flow and Profitability Summary

3.5.4

Sensitivity Analyses
Although a price estimate of the

cost of the fabrication of each chip has
been done to the best of our ability, price
fluctuation in the future is not something
that is readily accounted for.

It is

anticipated that some of the cost
estimates based on the current state of
the economy might not be consistent

Figure 3-25: Sensitivity Analysis: Chip Price vs. IRR

throughout the operating life of our plant.
For example, some of the raw material prices might change; the chip price might need to be
adjusted to respond to our competitors; gas price might go up due to short supply, increasing
transportation cost. Uncertainty clouds the future in every way, and it is generally common
practice to observe how much each
cost/revenue component causes the
investor rate of return (IRR) to change.
In another words, we want to see how
“resistant” IRR is in response to
“disturbances” in fixed cost, variable
costs, product price and initial capital

Figure 3-26 Sensitivity Analysis: Variable Cost vs. IRR.

investment. Amongst all of them, variable cost and product price are most likely subject to
change. Figure 3-25 shows the IRR at chip price ranging from $85 to $115. The steepness
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of the slope gives us an idea how sensitive IRR is in response to potential changes; the
closer to be horizontal implies the more stable IRR. Similarly, IRR versus variable cost is
graphed in Figure 3-26; the slope interpretation still holds. IRR sensitivity analyses with
changes in initial investment and fixed cost are not discussed here because it is anticipated
that unexpected changes to these two parameters are unlikely.

However, a full IRR

sensitivity analysis for all 4 parameters is included in the appendix for completion.

3.5.5

Capital Structure
Once the capital budgeting is complete, a decision on how to finance the project

needs to be made. There are generally two sources of financing: equity and debt. If a
combination of the two is used in our project, dividends are paid to stock holders while
interest is also paid out annually to bond holders. Because interest pay is tax deductable and
dividend is not, there is an asymmetry in the tax code that enables us to increase the NPV of
our company by borrowing money to finance our project. It should be noted that so far we
assume 100% ownership of the project. However, there is also risk associated with debt,
most notably the risk of bankruptcy. For these reasons, there must be an optimum equity to
debt ratio that maximizes the value of our company. The follow equation helps explain this
concept:
𝑉𝑉𝐿𝐿 = 𝑉𝑉𝑈𝑈 + 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 − 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃

where 𝑉𝑉𝐿𝐿 is the value of the company with leverage; PVTS represents the present value of

tax reduction due to debt financing; and PVCFD is the present value of cost of financial
distress (CFD).
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Numerical calculations will not be performed in regard to capital structure. The
purpose of this section is to qualitatively describe the value increase potential of our project
and the type of decisions we need to make beyond the preliminary design stage.

3.5.6

Conclusions
For 100% ownership of the project, the resulted net present value (NPV) of about

$45 million looks promising. The investor’s rate of return (IRR) of about 91% is extremely
lucrative and seemingly unreasonable.

However, it should be noted that the initial

investment for this project is relatively small compared to the cash inflow from sales. For
example, the total capital investment associated with the chip manufacture is about 11
million while the annual sales are $50 million. The IRR reflects the ratio of profit to the
initial investment. Generally, IRR is not used as the only guideline to accept or reject
mutually exclusive projects because it neglects the magnitude of the investment. On the
other hand, a positive NPV suggests that the project not only satisfies the required return of
15% (r=15%) but also gives an idea of how much extra value the project adds in addition to
the required return. Hence, we should accept this project with a positive NPV value of $45
million.
Although the NPV of the project indicates profitability in the long run, the initial
capital investment and the FDA approval costs at the first 3 years represent a huge cash
outflow at the beginning. Table 3-11 (Cash Flow Table) suggests the payback period is 6
years, after which the initial value put into the project is starts to be regained. In reality, a
project with this type of cash flow structure represents a risky investment. Nonetheless, for
a biomedical device development firm, this is rather typical and unavoidable.
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Sensitivity analyses are carried out on IRR with two and single inputs variation from
the expected value. The resulted IRR ranges from 75% to 110% (Appendix 7.7.4), which
looks favorable because of its implication that our project IRR is not susceptible to deviation
from expected sales or costs of operation.
The financial analysis in this report is performed by assuming 100% ownership. In
reality, this might not be actually feasible. Presumably, the project is financed with equity
and debt through venture capital. The capital structure with debt reduces our tax liability,
thus increases the value of our company.
Limitations have certainly been encountered during calculations of the financials. For
instance, the quotes obtained from raw material and equipment suppliers might not be
accurate because the sales representatives might not be aware of the magnitude of our
intended purchase, the discount rate estimated by the capital asset price model might
represent an underestimation of risk involved with our project, the expected market share
might not be as optimistic as 50%; or there might be some competitors that we are not aware
of. If this project is carried out beyond the preliminary design stage, these are some areas
that needed to be closely examined.
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Part 4 Development, Manufacturing, and Product-Introduction
Stages
4.1

FDA approval
Since the MCCRA System is considered to be a medical device, it is necessary to

obtain FDA approval before distribution to hospitals can begin. One of the first steps is
verify the class of our device. Since the system has multiple components and is responsible
for giving an accurate reading that will in turn be translated into a medication dosing amount,
it will not fall into the category of Class I devices. Class I encapsulates basic medical
instruments, such as tongue depressors. The proper functioning of these devices can mostly
be determined by basic inspection, and their failure is either relatively impossible or
presents no potential harm to the patient. However, Class III devices are those which if they
were to fail, could be harmful or even life-threatening, such as pacemakers. The MCCRA
System seems to fall in the category of a Class II device. It has the potential for failure and
its efficiency/safety must be demonstrated, but any malfunction of the device is not lifethreatening to the patient. Determination of the class of the medical device is important in
determining what paperwork needs to be filled out as well as what types of trials need to
take place in order to gain FDA approval. Product design specifications, manufacturing
protocols, and product prototypes must be submitted to the FDA in order for verification of
the MCCRA System as a Class II device. Once this verification is obtained, the necessary
paperwork can begin to be filled out and submitted and clinical trials can begin. (3)

4.1.1

Clinical Trials (56)
In order to gain FDA approval, it will need to be proved that the MCCRA System is

both safe and effective. One step is to try to prove Substantial Equivalence. This means
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that it will need to be shown that the basic mechanics of operation are the same as a product
that is already on the market, and therefore can already be assumed to have a similar level of
safeness and effectiveness.
The safeness and effectiveness of the MCCRA System will also be tested through a
series of clinical trials. In each Phase of the trials, every test subject will first be tested
without any additional medication, to serve as a control for that individual. Then testing
will be done with various amounts of clopidogrel dosing.
4.1.1.1 Phase I
In Phase I, approximately 75 test subjects will be used. Each subject will tested at
two different times. The first test will be run without giving any amount of medication to
the test subject. About a week later, the subject will be given a standard pre-angioplasty
dose of clopidogrel (300 mg (57)) and his blood will be reanalyzed the next day. This data
will be compiled and analyzed. The purpose of Phase I will primarily be to prove that the
MCCRA System is in fact safe and does show a variance in detection data as a result of
clopidogrel administration. It is estimated that this phase will take approximately 1 month
to run and analyze.
4.1.1.2 Phase II
In Phase II, the number of test subjects will be increase four-fold to approximately
300. In this series of testing, each subject will be tested 3 times. The first test will be run
without giving any amount of medication to the test subject. About one week later, the
subject will be administered one half of a standard dose of clopidogrel (150 mg) and his
blood will be tested the following day. Another two weeks later, the subject will be given a
- 102 -

full standard dose of clopidogrel (300 mg (57)), and his blood will be tested the next day. All
of these results will be compiled and analyzed. The primary intention of Phase II will be to
start proving the effectiveness of the device by demonstrating the sensitivity of the testing
(i.e. the variance of results due to variance of dosing amount) as well as to further prove the
safety of the device and procedure. It is estimated that this phase of trials and data analysis
will take approximately 5 months to complete.
4.1.1.3 Phase III
Phase III the number of test subjects will increase ten-fold from Phase II, to
approximately 3,000. In this phase, each subject will be tested four separate times. The
subject will first be tested before the administering of any amount of medication. One week
later, the subject will be administered one-quarter of the standard clopidogrel dose (75 mg)
and will be tested the next day. This will be repeated two weeks later for a one-half
standard dose (150 mg) and then two weeks after that for a full standard dose (300 mg).
Once again the data will be compiled and analyzed. The purpose of Phase III is to prove
that the device is ready for distribution to hospitals. The estimated duration of this phase is
one year.
4.1.1.4 Phase IV*
(N.B. Phase IV* is going to be denoted with an asterisk because although it is
technically a continuation of the clinical research, this phase actually takes place after FDA
approval has been obtained.) In Phase IV*, one MCCRA device and 25 disposable chips are
distributed (at no cost) to each of 50 hospitals nation-wide (the hospitals that receive the free
box and chips are the 50 hospitals with the highest number of angioplasties performed per
year in the United States.) By targeting the largest hospitals, our company has a better
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chance of capturing a large amount of the market. In addition, the hospitals that receive
these boxes will do so under the obligation of providing our company with feedback. By
analyzing the data of a bigger and broader range of patients, any possible variances that may
only occur in a small portion of the population may be discovered. The purpose of Phase
IV* is to investigate both this possibility, and also as a marketing tool to get the MCCRA
System into hospitals.

4.1.2

Manufacturing
In order to perform the clinical trials, the manufacturing facility must be operating at

partial capacity in order to produce the needed chips. In order to determine this capacity,
the number of MCCRA chips that will be required are tabulated in Table 4-1.

PHASE I
PHASE II
PHASE III

NUMBER
OF
SUBJECTS
REQUIRED
75
300
3,000

CHIPS
REQUIRED
FOR
TESTING
150
900
12,000

EXTRA
CHIPS
REQUIRED
(25%)
50
300
4,000

TOTAL
CHIPS
REQUIRED
200
1,200
16,000

TIME
FRAME
1 month
5 months
12 months

TOTALS

3,380

13,050

4,350

17,400

18 months

Table 4-1 Number of test subjects and chips required for each phase of the clinical trials, as well as the approximated
duration of each testing phase. The chips required for testing are based on the number of chips that are to be used per
test subject in each phase (Phase I = 2 chips per subject, Phase II = 3 chips per subject, Phase III = 4 chips per subject).
The extra chips that are factored in are to account for Quality Assurance Testing (1 chip tested per 4 chips produced).

The total number of chips required (with Quality Assurance Testing factored in) is
17,400. The rate of assumed chip failure must also be factored into this total (i.e. assume
that 1 chip fails due to defect for every 4 chips that are produced, or a 25% failure rate).
(See Equation 4-1)
𝟏𝟏𝟏𝟏,𝟒𝟒𝟒𝟒𝟒𝟒 𝒏𝒏𝒏𝒏𝒏𝒏−𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄
𝟕𝟕𝟕𝟕% 𝒐𝒐𝒐𝒐 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑

=

𝟐𝟐𝟐𝟐,𝟐𝟐𝟐𝟐𝟐𝟐 𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕𝒕 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄

𝟏𝟏𝟏𝟏𝟏𝟏% 𝒐𝒐𝒐𝒐 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑
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(4-1)

This means that at least 23,200 chips must be manufactured in order to accommodated those
needed in the clinical trials. Assuming that these are all produced in the first year of
manufacturing (so that production of chips does not hold up the execution of the trials), the
operation of the facility must be functioning at 4.2% of full operating capacity (See
Equation 4-2).
𝟐𝟐𝟐𝟐,𝟐𝟐𝟐𝟐𝟐𝟐 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏 𝒑𝒑𝒑𝒑𝒑𝒑 𝒚𝒚𝒚𝒚𝒚𝒚𝒚𝒚

𝟓𝟓𝟓𝟓𝟓𝟓,𝟎𝟎𝟎𝟎𝟎𝟎 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎 𝒑𝒑𝒑𝒑𝒑𝒑 𝒚𝒚𝒚𝒚𝒚𝒚𝒚𝒚 𝒂𝒂𝒂𝒂 𝒇𝒇𝒇𝒇𝒇𝒇𝒇𝒇 𝒐𝒐𝒐𝒐

= 𝟒𝟒. 𝟐𝟐% 𝒐𝒐𝒐𝒐 𝒇𝒇𝒇𝒇𝒇𝒇𝒇𝒇 𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐𝒐

(4-2)

For ease of calculation, this is approximated at 5% of the manufacturing facility’s full
operating capacity (or about 200 chips produced per day). In the next year, during which
the FDA approval process will still be underway, the facility will continue to operate at 5%
of full capacity. This will build up an inventory of MCCRA chips that will be stored and
used for distribution in the following year, enabling the shipment of chips to the 50 hospitals
that will receive free equipment right after FDA approval has been obtained, rather than
needing to delay distribution until fabrication of the chips is completed.
4.2

Recommendations for Future Studies
By utilizing the microfluidics technology, we allow ourselves to study one of the most

promising and intense areas of research. As new applications of this concept is discovered,
constant adaptation of our device is essential to keep pace with our competitors.
One of the advantages of our device is its expandability to other areas of applications
by simple modifications. For example, MRS 2395 could simply be replaced with its aspirin
counterpart (another anti-coagulant), so patients’ resistance to aspirin can also be measured.
Of course, mixing behavior of aspirin is to be characterized and the dissolution of it should
be studied; the box is being re-customized.
- 105 -

Clopidogrel’s usage has a potential to grow as its benefits are becoming known to the
rest of the world. Marketed in 110 countries, clopidogrel sales is currently ranked 2nd
worldwide and exhibiting a growth rate of 20%, fueling for demand for clopidogrel
resistance assay soon enough. Although the US is our major target market at this stage, we
should tailor a financial strategy to capture our share of the international market in a timely
fashion.
In this design report, the box manufacture is out sourced to an electronic supplier,
who makes a 30% profit by the synergy from sales of our chips. Rather than relying on an
out source supplier, we can set up a box manufacturing division in our own site, which
would facilitate the constant research and development aided improvements on our
technology.
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Part 7 Appendix
MSDS Reports

7.1

7.1.1

PDMS

Material Safety Data Sheet
Poly(dimethylsiloxane)

ACC# 95130

Section 1 - Chemical Product and Company Identification
MSDS Name: Poly(dimethylsiloxane)
Catalog Numbers: AC178440000, AC178442500, AC178445000
Synonyms: Simethicone; Dimethicone.
Company Identification:
Acros Organics N.V.
One Reagent Lane
Fair Lawn, NJ 07410
For information in North America, call: 800-ACROS-01
For emergencies in the US, call CHEMTREC: 800-424-9300

Section 2 - Composition, Information on Ingredients

CAS#
9016-00-6

Chemical Name

Percent

EINECS/ELINCS

100

unlisted

Poly(dimethylsiloxane)

Section 3 - Hazards Identification

EMERGENCY OVERVIEW
Appearance: clear liquid.
Caution! May cause eye, skin, and respiratory tract irritation. The toxicological properties
of this material have not been fully investigated.
Target Organs: None known.
Potential Health Effects
Eye: May cause eye irritation.
-1-

Skin: May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion: May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation: May cause respiratory tract irritation. May be harmful if inhaled.
Chronic: Adverse reproductive effects have been reported in animals. Animal studies have
reported the development of tumors.

Section 4 - First Aid Measures

Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally
lifting the upper and lower eyelids. If irritation develo ps, get medical aid.
Skin: Immediately flush skin with plenty of water for at least 15 minutes while removing
contaminated clothing and shoes. Get medical aid if irritation develops or persists.
Ingestion: Do not induce vomiting. Get medical aid if irritation or symptoms occur.
Inhalation: Remove from exposure and move to fresh air immediately. If not breathing,
give artificial respiration. If breathing is difficult, give oxygen. Get medical aid if cough or
other symptoms appear.
Notes to Physician: Treat symptomatically and supportively.

Section 5 - Fire Fighting Measures

General Information: As in any fire, wear a self-contained breathing apparatus in
pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or appropriate foam.
Flash Point: > 100 deg C (> 212.00 deg F)
Autoignition Temperature: Not applicable.
Explosion Limits, Lower:Not available.
Upper: Not available.
NFPA Rating: (estimated) Health: 1; Flammability: 1; Instability: 0

Section 6 - Accidental Release Measures

General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks: Absorb spill with inert material (e.g. vermiculite, sand or earth), then place
in suitable container. Provide ventilation. Do not let this chemical enter the environment.

Section 7 - Handling and Storage
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Handling: Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Avoid
ingestion and inhalation.
Storage: Store in a cool, dry place. Store in a tightly closed container.

Section 8 - Exposure Controls, Personal Protection

Engineering Controls: Facilities storing or utilizing this material should be equipped with
an eyewash facility and a safety shower. Use adequate ventilation to keep airborne
concentrations low.
Exposure Limits
Chemical Name

ACGIH

Poly(dimethylsiloxane) none listed

NIOSH

OSHA - Final PELs

none listed

none listed

OSHA Vacated PELs: Poly(dimethylsiloxane): No OSHA Vacated PELs are listed for this
chemical.
Personal Protective Equipment
Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by
OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard
EN166.
Skin: Wear appropriate protective gloves to prevent skin exposure.
Clothing: Wear appropriate protective clothing to prevent skin exposure.
Respirators: A respiratory protection program that meets OSHA's 29 CFR 1910.134 and
ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever
workplace conditions warrant respirator use.

Section 9 - Physical and Chemical Properties

Physical State: Liquid
Appearance: clear
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Vapor Density: Not available.
Evaporation Rate:Not available.
Viscosity: 100 cSt @ 25 deg C
Boiling Point: > 65 deg C @ 760 mmHg
Freezing/Melting Point:Not available.
Decomposition Temperature:Not available.
Solubility: Insoluble.
Specific Gravity/Density:0.965
Molecular Formula:Not available.
Molecular Weight:Not available.
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Section 10 - Stability and Reactivity

Chemical Stability: Stable under normal temperatures and pressures.
Conditions to Avoid: Incompatible materials, excess heat.
Incompatibilities with Other Materials: Strong oxidizing agents, strong acids, strong
bases.
Hazardous Decomposition Products: Carbon monoxide, carbon dioxide, silicon dioxide.
Hazardous Polymerization: Will not occur.

Section 11 - Toxicological Information

RTECS#:
CAS# 9016-00-6: TQ2690000
LD50/LC50:
Not available.
Carcinogenicity:
CAS# 9016-00-6: Not listed by ACGIH, IARC, NTP, or CA Prop 65.
Epidemiology: Tumorigenic effects have been reported in experimental animals.
Teratogenicity: No information found
Reproductive Effects: Adverse reproductive effects have occurred in experimental animals.
Mutagenicity: No information found
Neurotoxicity: No information found
Other Studies:

Section 12 - Ecological Information

Ecotoxicity: Fish: Rainbow trout: LC50 > 10000 mg/L; 96 Hr; UnspecifiedFish:
Bluegill/Sunfish: LC50 > 10000 mg/L; 96 Hr; Static bioassay Based on the Koc values, this
substance will be immobile in soil and is expected to adsorb to particulates and organic
matter in the water column. Rapid and extensive degradation is expected on dry surface
soils. Some microbial degradation of small compounds is likely. High molecular weight
poly(dimethylsiloxane) may bioconcentrate in aquatic organisms.
Environmental: Poly(dimethylsiloxane) with lower molecular weights exist in the
atmosphere in the vapor and particulate phases. Those with higher molecular weights exist
solely in the particulate phase. Particulate phase poly(dimethylsiloxane) will be removed
from the atmosphere by dry deposition while vapor phase poly(dimethylsiloxane) will be
degraded by the reaction with photochemically-produced hydroxyl radicals with a half-life of
32 hours.
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Physical: No information available.
Other: Do not empty into drains.

Section 13 - Disposal Considerations
Chemical waste generators must determine whether a discarded chemical is classified as a
hazardous waste. US EPA guidelines for the classification determination are listed in 40 CFR
Parts 261.3. Additionally, waste generators must consult state and local hazardous waste
regulations to ensure complete and accurate classification.
RCRA P-Series: None listed.
RCRA U-Series: None listed.

Section 14 - Transport Information

Shipping Name:

US DOT

Canada TDG

Not regulated.

Not regulated.

Hazard Class:
UN Number:
Packing Group:

Section 15 - Regulatory Information
US FEDERAL
TSCA
CAS# 9016-00-6 is not listed on the TSCA inventory. It is for research and development
use only.
Health & Safety Reporting List
None of the chemicals are on the Health & Safety Reporting List.
Chemical Test Rules
None of the chemicals in this product are under a Chemical Test Rule.
Section 12b
None of the chemicals are listed under TSCA Section 12b.
TSCA Significant New Use Rule
None of the chemicals in this material have a SNUR under TSCA.
CERCLA Hazardous Substances and corresponding RQs
None of the chemicals in this material have an RQ.
SARA Section 302 Extremely Hazardous Substances
None of the chemicals in this product have a TPQ.
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Section 313
No chemicals are reportable under Section 313.
Clean Air Act:
This material does not contain any hazardous air pollutants.
This material does not contain any Class 1 Ozone depletors.
This material does not contain any Class 2 Ozone depletors.
Clean Water Act:
None of the chemicals in this product are listed as Hazardous Substances under the CWA.
None of the chemicals in this product are listed as Priority Pollutants under the CWA.
None of the chemicals in this product are listed as Toxic Pollutants under the CWA.
OSHA:
None of the chemicals in this product are considered highly hazardous by OSHA.
STATE
CAS# 9016-00-6 is not present on state lists from CA, PA, MN, MA, FL, or NJ.
California Prop 65
California No Significant Risk Level: None of the chemicals in this product are listed.

European/International Regulations

European Labeling in Accordance with EC Directives
Hazard Symbols:
Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 9016-00-6: No information available.
Canada - DSL/NDSL
CAS# 9016-00-6 is listed on Canada's DSL List.
Canada - WHMIS
This product has a WHMIS classification of D2B.
This product has been classified in accordance with the hazard criteria of the Controlled
Products Regulations and the MSDS contains all of the information required by those
regulations.
Canadian Ingredient Disclosure List

Section 16 - Additional Information
MSDS Creation Date: 5/14/1999
Revision #4 Date: 1/11/2008
The information above is believed to be accurate and represents the best information currently available to us. However,
we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and
we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the
information for their particular purposes. In no event shall Fisher be liable for any claims, losses, or damages of any third
party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if
Fisher has been advised of the possibility of such damages.
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7.1.2

MRS 2395
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7.1.3

Collagen
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7.1.4

ADP
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7.1.5

Isopropanol
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7.1.6

Acetone
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7.2 Reagent Volume
Although we have calculated the surface concentrations of MRS 2395 required to reach the
targeted concentrations in the 4 streams (table x), the process of reagent deposition in liquid form
and drying creates uncertainties in how much reagents are actually left in anhydrous form on the
micro-channel. Before we conduct experimentation to study this process, the amount of MRS
2395 deposition is estimated to be 10 times the required amount in the flowing streams in this
report. The computation is performed on 1X IC50 of MRS 2395 as an example. The results are
tabulated in table x.
Known:
Targeted MRS concentration: IC50=3.6uM
Total Volume of Blood:

360 uL

Molecular Weight of MRS 2395:

440 g/mol

Find:
10 times the mass (mg) in this blood volume with the specified concentration.
Answer:
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑜𝑜 𝑀𝑀𝑀𝑀𝑆𝑆1×𝐼𝐼𝐼𝐼50 = 10 × 3.6𝑢𝑢𝑢𝑢 × 360𝑢𝑢𝑢𝑢 × 440𝑔𝑔/𝑚𝑚𝑚𝑚𝑚𝑚 = 0.0057𝑚𝑚𝑚𝑚

Target concentration

Amount deposited (mg)

0XIC50, or 0 um

0

0.1XIC50, or 0.36 uM

0.00057

1XIC50, or 3.6 uM

0.0057

10XIC50, or 36 uM

0.057

The total mass of MRS 2395 deposition is the sum of MRS 2395 in 8 streams:
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀2395 = 0.00057 × 2 + 0.0057 × 2 + 0.057 × 2 = 0.127mg

The diffusivity of ADP in water can be reasonably approximated as that of MRS 2395. Since
both ADP and MRS 2395 target P2Y 12 , ADP EC50 concentration can be inferred as in the same
order of magnitude as MRS 2395 IC50. The same amount of 1XIC50 ADP is deposited on the
channel, so the total mass of ADP is:
0.0057𝑚𝑚𝑚𝑚 × 8 = 0.0456𝑚𝑚𝑚𝑚
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7.3 Channel Bifurcation Calculations
The desired width of the final eight channels is 250 µm. The height for all of the channels is 60
µm. With this desired width in mind, the effective diameter (𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒 ) of the channel was calculated
width the equation below:
𝑤𝑤∗ℎ

𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒 = 2 ∗ �

(1)

𝜋𝜋

with w = width of the channel and h = height of the channel.
Once the effective diameter is known, the length of the channel can be calculated using Equation
2:
𝑙𝑙 = 5 ∗ 𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒

(2)

𝑟𝑟𝑝𝑝3 = 𝑟𝑟𝑑𝑑31 + 𝑟𝑟𝑑𝑑32 + ⋯ + 𝑟𝑟𝑑𝑑3𝑛𝑛 = 2 ∗ 𝑟𝑟𝑑𝑑3

(3)

𝑟𝑟𝑝𝑝 = 1.26 ∗ 𝑟𝑟𝑑𝑑

(4)

Working backwards using Murray’s Law, the effective diameter of the parent channel is
calculated from the effective diameter of the daughter channel.

Since both daughter channels have the same width, the equation can be simplified to:

After the effective diameter for the channel is calculated, the following equation is used to
calculate the width of the parent channel.
𝑤𝑤 = 𝜋𝜋 ∗

𝑑𝑑 𝑒𝑒𝑒𝑒𝑒𝑒 2

�

2

ℎ

�

(5)

After these calculations have been performed, this parent channel now becomes the daughter
channel for the next set of calculations and the previous steps are repeated until the first single
channel is reached. The calculations were performed in Microsoft Excel and the table below
shows the results,

Channel

Width
(µm)

Height
(µm)

Effective
Entry Length
Diameter (µm)
(µm)

Entry Length
(mm)

Final 8 Channels

250

60

138

691 =>

0.691

4 Channels After 2nd Split

397

60

174

871 =>

0.871

2 Channels After 1st Split

630

60

219

1097 =>

1.097

1000

60

276

1382 =>

1.382

1st Channel
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7.4

Dissolution of ADP and MRS 2395

Physical Constant Value @ 37 oC
𝛍𝛍

7*10-4 Pa s

𝛒𝛒

992.2 kg/m3

D AB

~10-9 m2/s

C ADP, required

3.6 uM

x (patch length)

150 um

u (velocity)

1 cm/s

W (width chan.)

250 um

.

𝑉𝑉 = 0.01 𝑚𝑚 × 60 × 10−6 𝑚𝑚 × 250 × 10−6 𝑚𝑚 = 1.5 × 10−10 𝑚𝑚3 /𝑠𝑠

Substituting all the physical constants:

⎛
𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨,𝒔𝒔 = ⎜

𝟏𝟏. 𝟓𝟓𝟓𝟓𝟓𝟓𝑽𝑽̇
𝟏𝟏

⎞
⎟ 𝑪𝑪𝑨𝑨𝑨𝑨𝑨𝑨 = 𝟐𝟐𝟐𝟐𝟐𝟐 𝒖𝒖𝒖𝒖

𝒖𝒖𝒖𝒖
𝝁𝝁 𝟑𝟑
�
� 𝑫𝑫𝑨𝑨𝑨𝑨 𝑾𝑾
𝝆𝝆𝑫𝑫
𝒗𝒗
𝑨𝑨𝑨𝑨
⎝
⎠
�

All other 2 surface concentrations of ADP associated with the 2 specified ADP in-stream
concentrations are computed by substituting C ADP with 0.36 uM and 36 uM.
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7.5 Runtime Calculations for Whole Blood Volume
Based on the widths and shear rates of the channels which model the flow of whole blood in the
body, the flow rate calculated was 1 cm/s. Using this flow rate, the volumetric flow rate is
calculated below for one channel.
𝑐𝑐𝑐𝑐3
𝑚𝑚3 1,000,000,000 𝜇𝜇𝜇𝜇
𝑐𝑐𝑐𝑐
−10
= �1.5 ∗ 10
��
�1 � (. 025 𝑐𝑐𝑐𝑐)(. 006 𝑐𝑐𝑐𝑐) = .00015
�
𝑚𝑚3
𝑠𝑠
𝑠𝑠
𝑠𝑠
𝜇𝜇𝜇𝜇
= .15
𝑠𝑠
where velocity = 1

𝑐𝑐𝑐𝑐
𝑠𝑠

, width = .025 cm, and height = .006 cm.

The total volumetric flow rate for eight channels is then
�. 15

𝜇𝜇𝜇𝜇
𝜇𝜇𝜇𝜇
� (8 𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎) = 1.2
𝑠𝑠
𝑠𝑠

The amount of whole blood needed for all eight channels to flow for one minute is calculated
below.

If the channels run for 5 minutes,

�1.2
�72

𝜇𝜇𝜇𝜇 60 𝑠𝑠
𝜇𝜇𝜇𝜇
��
� = 72
𝑠𝑠
𝑚𝑚𝑚𝑚𝑚𝑚
𝑚𝑚𝑚𝑚𝑚𝑚

𝜇𝜇𝜇𝜇
� (5 𝑚𝑚𝑚𝑚𝑚𝑚) = 360 𝜇𝜇𝜇𝜇
𝑚𝑚𝑚𝑚𝑚𝑚

Extra blood is needed to verify that the collagen strip is kept covered with blood so the results
are free of experimental error. It is assumed that an extra 20 seconds of blood per channel would
be sufficient.
(20 𝑠𝑠) �1.2

𝜇𝜇𝜇𝜇
� (8 𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎) = (192 𝜇𝜇𝜇𝜇)
𝑠𝑠

Therefore the total amount of blood being used is

192 𝜇𝜇𝜇𝜇 + 360 𝜇𝜇𝜇𝜇 = 552 𝜇𝜇𝜇𝜇

The waste reservoir volume has ample amount of room for this volume of blood. The volume of
the waste reservoir is calculated below.
(. 25 𝑐𝑐𝑐𝑐)(3 𝑐𝑐𝑐𝑐)(2 𝑐𝑐𝑐𝑐) = (1.5 𝑐𝑐𝑐𝑐3 ) �

where height = .25 cm, width = 3cm, and length = 2 cm.
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1,000 𝜇𝜇𝜇𝜇
� = 1,500 𝜇𝜇𝜇𝜇
𝑐𝑐𝑐𝑐3

7.6

7.6.1

Image J Analysis
5µM MRS 2395

High
Low
B
High
Low
Clot
C-B
(C-B)/B
0001
1345
1330 1337.5
1586
1566
1576
238.5 0.178318
0002
1346
1328
1337
1562
1541 1551.5
214.5 0.160434
0003
1353
1338 1345.5
1623
1604 1613.5
268 0.199182
0004
1344
1331 1337.5
1589
1571
1580
242.5 0.181308
0005
1351
1314 1332.5
1613
1560 1586.5
254 0.190619
0006
1343
1308 1325.5
1599
1546 1572.5
247 0.186345
0007
1340
1305 1322.5
1576
1521 1548.5
226 0.170888
0008
1349
1248 1298.5
1580
1468
1524
225.5 0.173662
0009
1348
1292
1320
1634
1528
1581
261 0.197727
0010
1350
1260
1305
1623
1543
1583
278 0.213027
0011
1343
1270 1306.5
1636
1523 1579.5
273 0.208955
0012
1359
1247
1303
1601
1525
1563
260
0.19954
0013
1348
1280
1314
1622
1518
1570
256 0.194825
0014
1348
1289 1318.5
1622
1512
1567
248.5 0.188472
0015
1350
1268
1309
1617
1498 1557.5
248.5
0.18984
0016
1350
1258
1304
1641
1506 1573.5
269.5 0.206672
0017
1348
1253 1300.5
1654
1540
1597
296.5 0.227989
0018
1344
1227 1285.5
1620
1486
1553
267.5
0.20809
0019
1350
1217 1283.5
1645
1527
1586
302.5 0.235684
0020
1344
1223 1283.5
1629
1486 1557.5
274 0.213479
0021
1341
1200 1270.5
1622
1469 1545.5
275
0.21645
0022
1341
1251
1296
1598
1500
1549
253 0.195216
0023
1309
1216 1262.5
1571
1430 1500.5
238 0.188515
0024
1299
1205
1252
1590
1440
1515
263 0.210064
0025
1284
1207 1245.5
1589
1467
1528
282.5 0.226817
0026
1325
1230 1277.5
1620
1502
1561
283.5 0.221918
0027
2269
2249
2259
2755
2684 2719.5
460.5 0.203851
0028
2221
2142 2181.5
2663
2598 2630.5
449 0.205822
0029 Contaminated
0030
1339
1317
1328
1671
1533
1602
274 0.206325
0031
1359
1327
1343
1674
1582
1628
285 0.212211
0032
1356
1330
1343
1657
1581
1619
276
0.20551
0033
1370
1348
1359
1704
1598
1651
292 0.214864
0034
1361
1328 1344.5
1664
1540
1602
257.5 0.191521
0035
1357
1321
1339
1671
1574 1622.5
283.5 0.211725
0036
1359
1323
1341
1678
1584
1631
290 0.216257
0037
1346
1310
1328
1702
1615 1658.5
330.5
0.24887
0038
1323
1286 1304.5
1670
1591 1630.5
326 0.249904
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Time
(sec)
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
150
155
160
165
170
175
180
185
190

0039
0040
0041
0042
0043
0044
0045
0046
0047
0048
0049
0050
0051
0052
0053
0054
0055
0056
0057
0058
0059
0060

7.6.2
0001
0002
0003
0004
0005
0006
0007
0008
0009
0010
0011
0012
0013
0014
0015
0016

1338
1345
1347
1347
1355
1355
1333
1334
1333
1329
1322
1332
1329
1331
1318
1312
1316
1290
1304
1287
1292
1276

1301
1301
1318
1310
1297
1317
1287
1297
1295
1292
1287
1301
1293
1298
1275
1275
1269
1263
1271
1259
1248
1254

1319.5
1323
1332.5
1328.5
1326
1336
1310
1315.5
1314
1310.5
1304.5
1316.5
1311
1314.5
1296.5
1293.5
1292.5
1276.5
1287.5
1273
1270
1265

1710
1705
1703
1708
1730
1707
1729
1673
1689
1698
1655
1737
1675
1666
1685
1678
1687
1669
1668
1646
1649
1657

1604
1609
1620
1636
1650
1588
1592
1608
1609
1607
1597
1655
1637
1588
1609
1605
1603
1597
1609
1573
1584
1542

1657
1657
1661.5
1672
1690
1647.5
1647.5
1640.5
1649
1652.5
1626
1696
1656
1627
1647
1641.5
1645
1633
1638.5
1609.5
1616.5
1599.5

337.5
334
329
343.5
364
311.5
337.5
325
335
342
321.5
379.5
345
312.5
350.5
348
352.5
356.5
351
336.5
346.5
334.5

0.255779
0.252457
0.246904
0.258562
0.27451
0.233159
0.257634
0.247054
0.254947
0.260969
0.246455
0.288264
0.263158
0.237733
0.270343
0.269037
0.272727
0.279279
0.272621
0.264336
0.272835
0.264427

195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300

10 µM MRS 2395
High
Low
B
High
Low
Clot
C-B
(C-B)/B
1756 1707 1731.5
1856 1796
1826
94.5 0.054577
1754 1710
1732
1839 1783
1811
79 0.045612
1753 1716 1734.5
1832 1796
1814
79.5 0.0458345
1760 1709 1734.5
1853 1769
1811
76.5 0.0441049
1749 1710 1729.5
1828 1778
1803
73.5 0.0424978
1749 1700 1724.5
1829 1776 1802.5
78 0.0452305
1721 1647
1684
1821 1743
1782
98 0.0581948
1718 1676
1697
1797 1759
1778
81 0.0477313
1716 1669 1692.5
1810 1750
1780
87.5 0.0516987
1705 1650 1677.5
1801 1742 1771.5
94 0.0560358
1719 1636 1677.5
1807 1718 1762.5
85 0.0506706
1704 1638
1671
1793 1719
1756
85 0.0508677
1727 1633
1680
1807 1724 1765.5
85.5 0.0508929
1722 1632
1677
1821 1723
1772
95 0.0566488
1720 1666
1693
1818 1730
1774
81 0.0478441
1745 1670 1707.5
1834 1780
1807
99.5 0.0582723
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Time
(sec)
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80

0017
0018
0019
0020
0021
0022
0023
0024
0025
0026
0027
0028
0029
0030
0031
0032
0033
0034
0035
0036
0037
0038
0039
0040
0041
0042
0043
0044
0045
0046
0047
0048
0049
0050
0051
0052
0053
0054
0055
0056
0057
0058
0059

1727
1731
1731
1764
1790
1788
1795
1788
1797
1794
1805
1794
1796
1809
1808
1783
1798
1791
1787
1798
1782
1789
1800
1791
1791
1791
1775
1797
1788
1778
1784
1774
1777
1774
1764
1766
1779
1760
1767
1767
1748
1778
1756

1678
1684
1666
1708
1743
1728
1672
1733
1716
1755
1759
1715
1753
1753
1739
1753
1735
1690
1732
1751
1715
1740
1699
1703
1743
1753
1689
1742
1711
1655
1660
1657
1728
1711
1707
1712
1664
1592
1667
1652
1697
1651
1678

1702.5
1707.5
1698.5
1736
1766.5
1758
1733.5
1760.5
1756.5
1774.5
1782
1754.5
1774.5
1781
1773.5
1768
1766.5
1740.5
1759.5
1774.5
1748.5
1764.5
1749.5
1747
1767
1772
1732
1769.5
1749.5
1716.5
1722
1715.5
1752.5
1742.5
1735.5
1739
1721.5
1676
1717
1709.5
1722.5
1714.5
1717

1853
1840
1862
1914
1934
1933
1954
1959
1972
1961
1984
1973
1961
1988
1976
1966
1966
1987
1966
1968
1964
1976
1964
1976
1970
1958
1950
1966
1954
1953
1960
1948
1964
1952
1946
1943
1960
1952
1952
1955
1946
1962
1959

1779
1776
1764
1829
1841
1842
1827
1853
1872
1851
1903
1882
1889
1891
1876
1908
1903
1872
1877
1905
1817
1869
1907
1848
1905
1898
1888
1862
1887
1878
1882
1853
1882
1821
1879
1859
1787
1848
1869
1892
1869
1904
1892
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1816
1808
1813
1871.5
1887.5
1887.5
1890.5
1906
1922
1906
1943.5
1927.5
1925
1939.5
1926
1937
1934.5
1929.5
1921.5
1936.5
1890.5
1922.5
1935.5
1912
1937.5
1928
1919
1914
1920.5
1873
1921
1900.5
1923
1886.5
1912.5
1901
1873.5
1900
1910.5
1923.5
1907.5
1933
1925.5

113.5
100.5
114.5
135.5
121
129.5
157
145.5
165.5
131.5
161.5
173
150.5
158.5
152.5
169
168
189
162
162
142
158
186
165
170.5
156
187
144.5
171
156.5
199
185
170.5
144
177
162
152
224
193.5
214
185
218.5
208.5

0.0666667
0.058858
0.0674124
0.078053
0.068497
0.0736633
0.0905682
0.082647
0.0942215
0.0741054
0.0906285
0.0986036
0.0848126
0.0889949
0.0859882
0.0955882
0.0951033
0.1085895
0.0920716
0.0912933
0.0812125
0.0895438
0.1063161
0.0944476
0.0964912
0.0880361
0.1079677
0.0816615
0.0977422
0.0911739
0.1155633
0.1078403
0.0972896
0.0826399
0.1019879
0.093157
0.0882951
0.1336516
0.1126966
0.1251828
0.107402
0.1274424
0.1214327

85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295

0060

7.6.3
0001
0002
0003
0004
0005
0006
0007
0008
0009
0010
0011
0012
0013
0014
0015
0016
0017
0018
0019
0020
0021
0022
0023
0024
0025
0026
0027
0028
0029
0030
0031
0032
0033
0034
0035
0036
0037

1769

1704

1736.5

1962

1870

1916

179.5 0.1033688

300

50 µM MRS 2395
Time
High
Low
B
High
Low
Clot
C-B
(C-B)/B
(sec)
1824 1768
1796 1936
1842
1889
93 0.051782
5
1821 1772
1796.5 1932
1875
1903.5
107 0.05956
10
1816 1789
1802.5 1909
1888
1898.5
96 0.053259
15
1759 1737
1748 1883
1846
1864.5 116.5 0.066648
20
1772 1731
1751.5 1914
1796
1852 100.5 0.057379
25
1779 1740
1759.5 1901
1831
1866 106.5 0.060529
30
1788 1757
1772.5 1897
1808
1852.5
80 0.045134
35
1807 1766
1786.5 1906
1851
1878.5
92 0.051497
40
1810 1753
1781.5 1914
1819
1866.5
85 0.047713
45
1796 1770
1783 1918
1816
1867
84 0.047112
50
1814 1768
1791 1917
1820
1868.5
77.5 0.043272
55
1807 1766
1786.5 1911
1842
1876.5
90 0.050378
60
1799 1767
1783 1910
1869
1889.5 106.5 0.059731
65
1789 1752
1770.5 1899
1857
1878 107.5 0.060717
70
1786 1741
1763.5 1895
1854
1874.5
111 0.062943
75
1775 1730
1752.5 1889
1852
1870.5
118 0.067332
80
1786 1730
1758 1879
1823
1851
93 0.052901
85
1782 1725
1753.5 1878
1840
1859 105.5 0.060165
90
1760 1720
1740 1873
1840
1856.5 116.5 0.066954
95
1765 1716
1740.5 1872
1750
1811
70.5 0.040506
100
1747 1705
1726 1863
1762
1812.5
86.5 0.050116
105
1752 1710
1731 1856
1809
1832.5 101.5 0.058637
110
1753 1696
1724.5 1846
1808
1827 102.5 0.059438
115
1774 1742
1758 1851
1797
1824
66 0.037543
120
1749 1688
1718.5 1871
1802
1836.5
118 0.068665
125
1762 1691
1726.5 1859
1709
1784
57.5 0.033304
130
1763 1628
1695.5 1828
1717
1772.5
77 0.045414
135
1775 1697
1736 1849
1785
1817
81 0.046659
140
1748 1694
1721 1876
1714
1795
74 0.042998
145
1746 1689
1717.5 1860
1799
1829.5
112 0.065211
150
1781 1686
1733.5 1878
1815
1846.5
113 0.065186
155
1759 1681
1720 1840
1749
1794.5
74.5 0.043314
160
1767 1712
1739.5 1845
1767
1806
66.5 0.038229
165
1762 1689
1725.5 1873
1801
1837 111.5 0.064619
170
1729 1674
1701.5 1842
1800
1821 119.5 0.070232
175
1757 1691
1724 1862
1801
1831.5 107.5 0.062355
180
1762 1685
1723.5 1841
1806
1823.5
100 0.058021
185
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0038
0039
0040
0041
0042
0043
0044
0045
0046
0047
0048
0049
0050
0051
0052
0053
0054
0055
0056
0057
0058
0059
0060

1764
1747
1751
1756
1736
1738
1744
1741
1746
1764
1734
1745
1755
1725
1729
1724
1734
1732
1727
1735
1727
1729
1727

1675
1650
1678
1656
1668
1638
1667
1699
1646
1723
1700
1692
1708
1674
1680
1685
1656
1653
1668
1668
1669
1686
1682

1719.5
1698.5
1714.5
1706
1702
1688
1705.5
1720
1696
1743.5
1717
1718.5
1731.5
1699.5
1704.5
1704.5
1695
1692.5
1697.5
1701.5
1698
1707.5
1704.5

1874
1871
1892
1873
1855
1872
1875
1875
1881
1885
1871
1888
1898
1898
1894
1898
1903
1936
1929
1954
1952
1962
1971

1802
1812
1791
1780
1780
1769
1735
1840
1825
1837
1830
1806
1842
1828
1821
1832
1827
1801
1835
1830
1827
1839
1850
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1838
1841.5
1841.5
1826.5
1817.5
1820.5
1805
1857.5
1853
1861
1850.5
1847
1870
1863
1857.5
1865
1865
1868.5
1882
1892
1889.5
1900.5
1910.5

118.5
143
127
120.5
115.5
132.5
99.5
137.5
157
117.5
133.5
128.5
138.5
163.5
153
160.5
170
176
184.5
190.5
191.5
193
206

0.068915
0.084192
0.074074
0.070633
0.067861
0.078495
0.058341
0.079942
0.092571
0.067393
0.077752
0.074775
0.079988
0.096205
0.089762
0.094163
0.100295
0.103988
0.108689
0.11196
0.11278
0.113031
0.120857

190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300

7.7

7.7.1

Equipment Sizing
Oven

Daily Chip Output (DCO) at 100% production capacity:
𝐷𝐷𝐷𝐷𝐷𝐷 =

𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖
500,000 𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖
= 2000
250 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑜𝑜𝑜𝑜 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜
𝑑𝑑𝑑𝑑𝑑𝑑

There are 2 shifts, morning shift and afternoon shift, per day.
𝐶𝐶ℎ𝑖𝑖𝑖𝑖 𝑝𝑝𝑝𝑝𝑝𝑝 𝑠𝑠ℎ𝑖𝑖𝑖𝑖𝑖𝑖 =

2000 𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖
= 1000 𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖
2 𝑠𝑠ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖

With the chip surface dimension of 4 cm by 6 cm, the theoretical minimum space is:
𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚 = 1000 × 4 𝑐𝑐𝑐𝑐 × 6𝑐𝑐𝑐𝑐 = 2.4 𝑚𝑚2

Considering the fact that there are gaps between individual chips on manifold, we multiple a
factor of 1.5 to obtain the actual space required from an oven.
𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 = 2.4 𝑚𝑚2 × 1.5 = 3.6 𝑚𝑚2 ≈ 6.2 𝑓𝑓𝑓𝑓 × 6.2 𝑓𝑓𝑓𝑓

As shown above, this is equivalent to 6.2 ft by 6.2 capacity oven. If two manifolds were to be
stacked upon one another before being inserted into the oven, the space required is halved.

7.7.2

Stirred Tank

The volume of PDMS per batch is about 10 L and a factor of 1.5 is multiplied to leave extra
space to buffer again overflow:

7.7.3

𝑉𝑉 = 10 𝐿𝐿 × 1.5 = 15 𝐿𝐿

Storage

Monthly Chip Output (MCO) is computed as:
𝑀𝑀𝑀𝑀𝑀𝑀 =

500,000 𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖
𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖
= 42,000
12 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀ℎ𝑠𝑠
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀ℎ

One of the operating assumptions is that our inventory is shipped to clients every month, so the
storage unit should be able to accommodate the volume of MCO, which is computed as:
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚 ,𝑀𝑀𝑀𝑀𝑀𝑀 = 42,000

𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖
× 6 𝑐𝑐𝑐𝑐 × 4 𝑐𝑐𝑐𝑐 × 1 𝑐𝑐𝑐𝑐 = 35 𝑓𝑓𝑓𝑓 3
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀ℎ

A factor of 2.0 is multiplied with 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚 ,𝑀𝑀𝑀𝑀𝑀𝑀 to consider voided volume in the storage unit:

𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎 ,𝑀𝑀𝑀𝑀𝑀𝑀 = 35 𝑓𝑓𝑓𝑓 3 × 2.0 = 70 𝑓𝑓𝑓𝑓 3
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7.7.4

Profitability Input Summary
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7.7.5

Two Variable Sensitivity Analysis
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7.8

Prior Microfluidic Chip Designs
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7.9

7.9.1

Consulting with Thomas Kohli
Recurring Costs for Box Manufacture

Recurring Costs

based on a Quantity of 1

PC
Hardware

$2,000

Software

$2,000

Component & Instrumentation Selection
Power Supply
Vacuum
LED
Detector
Interlock Switch
Box
Wire

$50
$100
$25 x8
$25
$25
$100
$200

Mechanical Parts
Box Mods
Chip Hoder Brackets
Chip Vacuum Cover
LED Bracket
Detector Bracket
Box Lid with Interlock
Silk Screens/Labeling
Chip
Assembly Labor
System Integration and Verification
User Manual Desciption & Maintenance
Certification

assumes full version of LabVIEW; much
cheaper alternative availabe but I am
too tired to check now. DAD

$250
$200
$250
$200
$200
$250
$250
????
40 hours
40 hours
40 hours
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assume all mechanical parts are
machined parts. Usually a setup charge
is required.
$125 setup & remainder is cost of item.

silk screen $125 per screen

7.10 E-mail Regarding Plavix Test System Diagrams
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7.11 Velocity Profile within a Rectangular Microchannel

(58)

The shear rate at the wall can be found by taking the derivatives of the above expression with
respect to y and z, evaluated at y=0, and z=0.
A pre-programmed excel spreadsheet made possible by Sean Maloney computed the linear
velocity (u) corresponding to a average wall shear rate of 1000 s-1 to be 1 cm in a 250um by 60
um microchannel.
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7.12 Manufacturing Equipment List

Wisconsin Oven Corporation Ltd.
SWN Series Normal Duty Walk-In Oven
Model 610-6
Specifications:
CFM X
100

Horsepower

KilowattsElectric

BTU’s
X
1,000Gas

Cubic
Feet of
Chamber

Chamber
Width

Chamber
Width

Chamber
Height

34

3

72

400

360

6’

10’

6’

Outside Width

Outside
Length

Outside
Height

Approximate
Weight

8’

11’

9’9”

4,474 lbs.

Electro-Technic Products
High-Frequency Corona Surface Treater
Model BD-80

- 60 -

7.13 Communication with David Burke of Wisconsin Oven Corporation
----- Forwarded message from dj_burke@comcast.net ----Date: Thu, 2 Apr 2009 14:51:22 -0400
From: David Burke <dj_burke@comcast.net>
Subject: Your inquiry to Wisc Oven Corp
To: paoba@seas.upenn.edu
Cc: "Hank Hubbell (WOC)" <hhubbell@wisoven.com>
Hello Paul,
Per your inquiry to Wisconsin Oven Corporation I've attempted to reach you a couple of times via phone and in
order to assist you, will need to find out more about your application. Per your request, attached is a brochure of our
SWN Series of batch ovens. If you refer to line 43 you will find the model SWN-610-6 you inquired
about. However we don't know if you want it heated by electricity or gas and there are a lot of other questions we
will need answered in order to best assist you.
The price range for this oven without any options would be in the area of $22,000.00 without any options for an
electrically heated oven and around $24,000.00 for a gas fired unit. All our ovens are shipped FOB: E Troy WI,
freight collect
If you would please contact me at your convenience to discuss your application and installation area in greater detail,
I will be able to determine what will be required and provide you with more firm pricing.
Thank you for your interest in our thermal process related equipment, we look forward to working with you.
Regards,
David J. Burke
WOC District Sales Rep
Torrid Enterprises Inc.
978-779-0317
dj_burke@comcast.net
www.torridenterprises.com
----- End forwarded message ----Paul A. O'Brien
University of Pennsylvania
School of Engineering and Applied Science '09
paoba@seas.upenn.edu
(845) 527-0886
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